A Phase 1 interventional study of acapatamab and Pembrolizumab in Metastatic Castration-resistant Prostate Cancer and Prostate Cancer, sponsored by Amgen. Terminated at 30 sites in 10 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.
Sponsored by Amgen · Phase 1, Interventional, and Treatment
How we know · 12 judgments · 2 readings being read again
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Prostatic Neoplasms by Amgen — 4 open to participants now, 7 under way, 2 of them phase 3. Prostatic Neoplasms · Amgen.
Among the 23 studies in Prostatic Neoplasms by Amgen, this one is the 8th largest by enrollment of the 21 interventional ones that give a count, is the only one that started in 2019, is one of 9 in phase 1, and was the 14th registered.
7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →4 of the 23 studies in Prostatic Neoplasms by Amgen are open now, in 12 countries. Recruiting first, the newest first:
Amgen · Sites in United States, Australia
Ages 18+ · Men only
Amgen · Sites in United States, Australia, Austria and 15 more countries
Ages 18+ · Men only
Amgen · Sites in United States, Germany
Ages 18+ · Men only
Amgen · Sites in United States, Australia, China and 7 more countries
Ages 18+ · Men only
By country, each count listing its studies:
Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 4 · Phase 3 9
First in 1999; this study’s year is marked. 1 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 212 is above the median of 60 across 5,358 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 64 across the 21 interventional studies, 1,262 across the 1 observational. Of the 15 that completed or were terminated, 11 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 167 (68%) have results posted.
3 of the studies in Prostatic Neoplasms by Amgen that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06613100AmgenEvaluation of Neoadjuvant Xaluritamig in Localized Prostate Cancer | 2027-02-17 |
| NCT06555796AmgenEvaluation of Xaluritamig in High-Risk, Biochemically Recurrent, Non-metastatic Castrate-sensitive Prostate Cancer | 2027-03-13 |
| NCT07140900AmgenStudy Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer | 2027-10-27 |
Add all 3 to your calendar (.ics) → With an account.
Among the 23 studies in Prostatic Neoplasms by Amgen, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A phase 1 study evaluating the safety, tolerability, pharmacokinetics, and efficacy of prostate specific membrane antigen half-life extended bispecific T-cell engager acapatamab in subjects with metastatic castration-resistant prostate cancer, and to determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D).
This is a phase I, first-in-human study to evaluate the safety and tolerability of acapatamab; a half-life extended (HLE) bispecific T-cell engager (BiTE®) construct, alone and in combination with pembrolizumab, etanercept prophylaxis and cytochrome P450 (CYP) phenotyping cocktail in subjects with metastatic castration-resistant prostate cancer.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
All Parts
Inclusion Criteria:
Exclusion Criteria:
Part 2 only:
Part 3 only:
- Evidence of active tuberculosis on chest radiograph within 3 months prior to the first dose of product
Part 6 only:
Subjects are excluded from this cohort if any of the following additional criteria apply:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Part 1 dose-exploration: acapatamab is administered intravenously. The dose-exploration phase of the study will estimate the MTD of acapatamab. RP2D may be identified based on emerging safety, efficacy, and pharmacodynamic data prior to reaching an MTD.
Drug: acapatamab
Part 1 dose-expansion: acapatamab is administered intravenously at the MTD/RP2D.
Drug: acapatamab
Part 2: acapatamab is administered intravenously at the MTD/RP2D. Pembrolizumab will be administered intravenously.
Drug: acapatamab · Drug: Pembrolizumab
Part 3: acapatamab is administered intravenously at RP2D/MTD levels. Etanercept will be administered subcutaneously in cycle 1 only.
Drug: acapatamab · Drug: Etanercept
Part 4: acapatamab is administered intravenously at RP2D/MTD with 24-hour monitoring.
Drug: acapatamab
Part 5: acapatamab is administered intravenously at RP2D/MTD in an outpatient setting with 8-hour monitoring.
Drug: acapatamab
Part 6: acapatamab is administered intravenously at RP2D/MTD. A CYP phenotyping cocktail will be administered orally.
Drug: acapatamab · Drug: Cytochrome P450 (CYP) Cocktail
Investigational immunotherapy for the treatment of metastatic castration-resistant prostate cancer
Also known as: PSMA Targeted Therapy
Combined with acapatamab for investigational treatment of mCRPC
Also known as: PD-1 inhibitor
Prophylaxis for acapatamab-related cytokine release syndrome.
Also known as: TNF-alpha inhibitor
Evaluate the effect of co-administration of multiple dosing of acapatamab on plasma
Also known as: Cooperstown 5+1 CYP phenotyping cocktail
Number of Participants With a Dose Limiting Toxicity (DLT)- Parts 1 and 2
DLTs are defined as any adverse event with an onset within first 28 days following first dose of AMG 160 monotherapy (Part 1) or in combination with pembrolizumab (Part 2) with any of the following criteria unless clearly attributable to causes other than AMG 160 treatment: • grade 5 toxicity (eg, death not due to disease progression)
Time frame: Day 1 to 28 of Cycle 1 (length of cycle is 28 days)
Number of Participants With Treatment Emergent Adverse Events- Parts 1, 2, 3, 4, and 5
A treatment-emergent adverse event is one that occurs on or after the first dose of study treatment and up to 30 days after the last dose. Adverse events were graded using Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Any clinically significant changes in vital signs, electrocardiograms, and clinical laboratory tests were recorded as adverse events.
Time frame: Up to 30 days after the last dose of study drug, or start of new anti-cancer therapy, whichever occurs first
Objective Response (OR) Rate- Parts 1, 2, 3, 4, and 5
OR was defined as a partial response (PR) or complete response (CR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, confirmed by a repeat assessment at least 4 weeks later. Participants who did not experience a PR/CR or did not have any follow-up tumor assessments were regarded as non-responders.
Time frame: Up to 3 years
Prostate-specific Antigen (PSA) Response- Parts 1, 2, 3, 4, and 5
A PSA response (PSA 30) is defined as a ≥ 30% reduction from the baseline PSA, (PSA 50) is defined as a ≥ 50% reduction from the baseline PSA, (PSA 70) is defined as a ≥ 70% reduction from the baseline PSA, and (PSA 90) is defined as a ≥ 90% reduction from the baseline PSA. PSA response must be confirmed by a second consecutive value ≥ 3 weeks later.
Time frame: Up to 3 years
Duration of Response (DOR)-RECIST 1.1- Parts 1, 2, 3, 4, and 5
DOR is defined as the time from the date of an initial objective response per RECIST 1.1 to the earlier of progression or death. Participants who had not ended their response at the time of analysis had DOR censored at their last evaluable tumor assessment.
Time frame: Up to 3 years
Duration of PSA Response- Parts 1, 2, 3, 4, and 5
PSA DOR is defined as the time from the date of an initial PSA response (PSA 50) to the earlier of PSA progression or death. Subjects who have not ended their response at the time of analysis will have PSA DOR censored on the date of their last PSA measurement. This endpoint only applies to subjects with a PSA response (PSA 50).
Time frame: Up to 3 years
Percentage of Participants With 68Gallium (68Ga)-Prostate-specific Membrane Antigen (PSMA) Response Parts 1, 2, and 3
A Gallium PSMA-11 response is a ≥50% reduction from baseline in the maximum standardized uptake value (SUV) using 68Gallium (68Ga)-prostate-specific membrane antigen (PSMA)-11 positron emission tomography (PET)/computed tomography (CT).
Time frame: Up to 3 years
Percentage of Participants With F-fluorodeoxyglucose (FDG) Response- Parts 1, 2, and 3
A FDG PET response is a ≥50% reduction from baseline in the maximum SUV using 18F-FDG PET/CT.
Time frame: Up to 3 years
Time to Progression (Radiographic)- Parts 1, 2, 3, 4, and 5
Time to radiographic progression is defined as the time from study Day 1 until the first documentation of radiographic disease progression in the absence of subsequent anticancer therapy. Time to radiographic progression will be censored at the last evaluable post-baseline tumor assessment prior to subsequent anti-cancer therapy; otherwise, at study Day 1.
Time frame: Up to 3 years
Time to Progression (PSA)- Parts 1, 2, 3, 4, and 5
Time to PSA progression is defined as the interval from study Day 1 to PSA progression; otherwise, time to PSA progression is censored on the date of the last PSA measurement. If a participant has no baseline or no post-baseline PSA measurement, time to PSA progression will be censored at study Day 1.
Time frame: Up to 3 years
Progression Free Survival (Radiographic)- Parts 1, 2, 3, 4, and 5
Radiographic progression free survival (rPFS) is defined as the interval from study day 1 to the earlier of a radiographic progression or death from any cause; otherwise, rPFS is censored at the last evaluable tumor assessment date. If a subject has no post-baseline radiographic tumor assessment and a vital status of alive or unknown, rPFS will be censored at study day 1.
Time frame: Up to 3 years
Progression Free Survival (PSA)- Parts 1, 2, 3, 4, and 5
PSA PFS is defined as the interval from study day 1 to the earlier of a PSA progression or death from any cause; otherwise, PSA PFS is censored on the date of the last PSA measurement. If a subject has no baseline or no post-baseline PSA measurement and a vital status of alive or unknown, PSA PFS will be censored at study day 1.
Time frame: Up to 3 years
Overall Survival- Parts 1, 2, 3, 4, and 5
Overall survival (OS) is defined as the time from the date of study Day 1 until death due to any cause.
Time frame: Up to 3 years
Percentage of Participants With Circulating Tumor Cell Response (CTC0)- Parts 1, 2, 3, 4, and 5
CTC0 is defined as reduction of CTCs \> 0 to 0 at any post-baseline measurement. CTC0 response is applicable only for participants with baseline CTC \> 0.
Time frame: Up to 3 years
Percentage of Participants With CTC Conversion- Parts 1, 2, 3, 4, and 5
CTC conversion is defined as ≥ 5 CTCs/7.5 mL blood to ≤ 4 CTCs/7.5 mL blood at any post-baseline measurement. CTC conversion is applicable only for subjects with baseline CTC ≥ 5..
Time frame: Up to 3 years
Time to Symptomatic Skeletal Events (SSE)- Parts 1, 2, 3, 4, and 5
Time to SSE is defined as time from study day 1 to the first SSE. Otherwise, SSE is censored at the last dose date of AMG 160 or pembrolizumab or end of safety follow up date, whichever is later.
Time frame: Up to 3 years
Maximum Observed Concentration (Cmax) of AMG 160 - Parts 1, 2, and 3
Serum concentrations of AMG 160 were determined using a validated assay. Noncompartmental analysis was performed for the estimation of pharmacokinetic (PK) parameters. Concentrations below the lower limit of quantification (LLOQ) (0.0500 ng/mL) were set to zero before data analysis. PK parameters, including Cmax, Tmax, Cmin, AUClast, AUCtau, t1/2,z, were not estimated for Parts 4 and 5 because the PK sampling schedule in these parts was sparse and not designed to support parameter estimation.
Time frame: Cycle 1 Days 1, 8, 15, and 22; Cycle 2 Days 1 and 15 (sampling pre-dose up to 168 hours post-dose)
Time to Cmax (Tmax) of AMG 160- Parts 1, 2, and 3
Serum concentrations of AMG 160 were determined using a validated assay. Noncompartmental analysis was performed for the estimation of PK parameters. Concentrations below the LLOQ (0.0500 ng/mL) were set to zero before data analysis. Actual time post dose was used for calculations. PK parameters, including Cmax, Tmax, Cmin, AUClast, AUCtau, t1/2,z, were not estimated for Parts 4 and 5 because the PK sampling schedule in these parts was sparse and not designed to support parameter estimation.
Time frame: Cycle 1 Days 1, 8, 15, and 22; Cycle 2 Days 1 and 15 (sampling pre-dose up to 696 hours)
Minimum Serum Concentration (Cmin) of AMG 160- Parts 1, 2, and 3
Serum concentrations of AMG 160 were determined using a validated assay. Noncompartmental analysis was performed for the estimation of PK parameters. Concentrations below the LLOQ (0.0500 ng/mL) were set to zero before data analysis. PK parameters, including Cmax, Tmax, Cmin, AUClast, AUCtau, t1/2,z, were not estimated for Parts 4 and 5 because the PK sampling schedule in these parts was sparse and not designed to support parameter estimation.
Time frame: Cycle 1 Days 1, 8, 15, and 22; Cycle 2 Days 1 and 15 (sampling pre-dose up to 168 hours post-dose))
Area Under the Concentration-time Curve (AUC) From Time 0 to Last Quantifiable Concentration (AUClast) of AMG 160- Parts 1, 2, and 3
Serum concentrations of AMG 160 were determined using a validated assay. Noncompartmental analysis was performed for the estimation of PK parameters. Concentrations below the LLOQ (0.0500 ng/mL) were set to zero before data analysis. PK parameters, including Cmax, Tmax, Cmin, AUClast, AUCtau, t1/2,z, were not estimated for Parts 4 and 5 because the PK sampling schedule in these parts was sparse and not designed to support parameter estimation.
Time frame: Cycle 1 Days 1, 8, 15, and 22; Cycle 2 Days 1 and 15 (sampling pre-dose up to 168 hours post-dose))
AUC Over the Dosing Interval (AUCtau)- Parts 1, 2, and 3
Serum concentrations of AMG 160 were determined using a validated assay. Noncompartmental analysis was performed for the estimation of PK parameters. Concentrations below the LLOQ (0.0500 ng/mL) were set to zero before data analysis. PK parameters, including Cmax, Tmax, Cmin, AUClast, AUCtau, t1/2,z, were not estimated for Parts 4 and 5 because the PK sampling schedule in these parts was sparse and not designed to support parameter estimation.
Time frame: Cycle 1 Days 1, 8, 15, and 22; Cycle 2 Days 1 and 15 (sampling pre-dose up to 168 hours post-dose)
Terminal Half-life (t1/2,z) of AMG 160- Parts 1, 2, and 3
Serum concentrations of AMG 160 were determined using a validated assay. Noncompartmental analysis was performed for the estimation of PK parameters. Concentrations below the LLOQ (0.0500 ng/mL) were set to zero before data analysis. PK parameters, including Cmax, Tmax, Cmin, AUClast, AUCtau, t1/2,z, were not estimated for Parts 4 and 5 because the PK sampling schedule in these parts was sparse and not designed to support parameter estimation.
Time frame: Cycle 1 Days 1, 8, 15, and 22; Cycle 2 Days 1 and 15 (sampling pre-dose up to 168 hours post-dose)
Participants were enrolled from 05 Feb 2019 to 29 Jun 2023 at 26 centers in Australia, Austria, Belgium, Canada, France, Japan, the Netherlands, Singapore, and the United States.
| Milestone | Part 1A: AMG 160 Monotherapy 0.003 mg | Part 1A: AMG 160 Monotherapy 0.01 mg | Part 1A: AMG 160 Monotherapy 0.03 mg | Part 1A: AMG 160 Monotherapy 0.03 mg SD1 | Part 1A: AMG 160 Monotherapy 0.09 mg SD2 | Part 1A: AMG 160 Monotherapy 0.3 mg SD3 | Part 1A: AMG 160 Monotherapy 0.9 mg SD4 | Part 1A: AMG 160 Monotherapy 0.9 mg SD5 | Part 1A: AMG 160 0.9 mg + Tocilizumab SD6 | Part 1A: AMG 160 Monotherapy 0.9 mg SD7 | Part 1B1: AMG 160 Monotherapy 0.09 mg eIV1-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.3 mg eIV2-2d-Inf | Part 1B1: AMG 160 Monotherapy 0.3 mg eIV2-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.9 mg eIV3-2d-Inf | Part 1B1: AMG 160 Monotherapy 0.9 mg eIV3-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.6 mg eIV4-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.3 mg eIV5-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.3 mg eIV5-5d-Inf | Part 1B2: AMG 160 Monotherapy 0.09 mg eIVJC1-3d-Inf | Part 1B2: AMG 160 Monotherapy 0.3 mg eIVJC2-3d-Inf | Part 1: AMG Monotherapy Dose Expansion (DE) (0.3 mg) | Part 2: AMG 160 + Pembrolizumab 0.03 mg SDPC1 | Part 2: AMG 160 + Pembrolizumab 0.3 mg SDPC2 | Part 2: AMG 160 + Pembrolizumab 0.15 mg eIVPC3-3d-Inf | Part 2: AMG 160 + Pembrolizumab 0.3 mg eIVPC4-3d-Inf | Part 2: AMG 160 + Pembrolizumab 0.15 mg eIVPC3-3d-Inf D-RP2D | Part 3: AMG 160 With Cytokine Release Syndrome (CRS) Prophylaxis 0.9 mg SDEC1 | Part 3: AMG 160 With CRS Prophylaxis 0.3 mg eIVEC1-3d-Inf | Part 4: AMG 160 Monotherapy 0.3 mg 24HR | Part 5: AMG 160 Monotherapy 0.3 mg 8HR |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 3 | 4 | 1 | 3 | 6 | 4 | 4 | 4 | 3 | 4 | 6 | 4 | 3 | 2 | 1 | 4 | 4 | 6 | 4 | 7 | 56 | 6 | 3 | 5 | 7 | 3 | 3 | 3 | 26 | 23 |
| Completed | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 |
| Not completed | 3 | 4 | 0 | 3 | 5 | 4 | 4 | 4 | 3 | 4 | 6 | 4 | 3 | 2 | 1 | 4 | 4 | 6 | 4 | 7 | 55 | 6 | 3 | 5 | 7 | 3 | 3 | 3 | 24 | 23 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 1 | 5 | 0 | 0 | 0 | 2 | 0 | 1 | 1 | 5 | 3 |
| Withdrew: Sponsor decision | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 2 | 0 | 1 | 1 | 0 | 2 | 1 | 0 | 0 | 1 | 10 | 0 | 0 | 2 | 1 | 2 | 0 | 0 | 7 | 8 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 |
| Withdrew: Death | 3 | 4 | 0 | 3 | 4 | 2 | 4 | 3 | 3 | 4 | 3 | 3 | 2 | 1 | 1 | 2 | 3 | 4 | 4 | 5 | 40 | 6 | 3 | 3 | 4 | 1 | 1 | 2 | 11 | 11 |
DLTs are defined as any adverse event with an onset within first 28 days following first dose of AMG 160 monotherapy (Part 1) or in combination with pembrolizumab (Part 2) with any of the following criteria unless clearly attributable to causes other than AMG 160 treatment: • grade 5 toxicity (eg, death not due to disease progression)
| Participants | Part 1A: AMG 160 Monotherapy 0.003 mg | Part 1A: AMG 160 Monotherapy 0.01 mg | Part 1A: AMG 160 Monotherapy 0.03 mg | Part 1A: AMG 160 Monotherapy 0.03 mg SD1 | Part 1A: AMG 160 Monotherapy 0.09 mg SD2 | Part 1A: AMG 160 Monotherapy 0.3 mg SD3 | Part 1A: AMG 160 Monotherapy 0.9 mg SD4 | Part 1A: AMG 160 Monotherapy 0.9 mg SD5 | Part 1A: AMG 160 0.9 mg + Tocilizumab SD6 | Part 1A: AMG 160 Monotherapy 0.9 mg SD7 | Part 1B1: AMG 160 Monotherapy 0.09 mg eIV1-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.3 mg eIV2-2d-Inf | Part 1B1: AMG 160 Monotherapy 0.3 mg eIV2-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.9 mg eIV3-2d-Inf | Part 1B1: AMG 160 Monotherapy 0.9 mg eIV3-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.6 mg eIV4-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.3 mg eIV5-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.3 mg eIV5-5d-Inf | Part 1B2: AMG 160 Monotherapy 0.09 mg eIVJC1-3d-Inf | Part 1B2: AMG 160 Monotherapy 0.3 mg eIVJC2-3d-Inf | Part 1: AMG Monotherapy DE (Dose F) | Part 2: AMG 160 + Pembrolizumab 0.03 mg SDPC1 | Part 2: AMG 160 + Pembrolizumab 0.3 mg SDPC2 | Part 2: AMG 160 + Pembrolizumab 0.15 mg eIVPC3-3d-Inf | Part 2: AMG 160 + Pembrolizumab 0.3 mg eIVPC4-3d-Inf | Part 2: AMG 160 + Pembrolizumab 0.15 mg eIVPC3-3d-Inf D-RP2D |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With a Dose Limiting Toxicity (DLT)- Parts 1 and 2 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 1 | 2 | 1 | 2 | 0 | 0 | 4 | 0 | 1 | 0 | 1 | 0 |
OR was defined as a partial response (PR) or complete response (CR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, confirmed by a repeat assessment at least 4 weeks later. Participants who did not experience a PR/CR or did not have any follow-up tumor assessments were regarded as non-responders.
| Percentage of Participants | Part 1A: AMG 160 Monotherapy 0.003 mg | Part 1A: AMG 160 Monotherapy 0.01 mg | Part 1A: AMG 160 Monotherapy 0.03 mg | Part 1A: AMG 160 Monotherapy 0.03 mg SD1 | Part 1A: AMG 160 Monotherapy 0.09 mg SD2 | Part 1A: AMG 160 Monotherapy 0.3 mg SD3 | Part 1A: AMG 160 Monotherapy 0.9 mg SD4 | Part 1A: AMG 160 Monotherapy 0.9 mg SD5 | Part 1A: AMG 160 0.9 mg + Tocilizumab SD6 | Part 1A: AMG 160 Monotherapy 0.9 mg SD7 | Part 1B1: AMG 160 Monotherapy 0.09 mg eIV1-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.3 mg eIV2-2d-Inf | Part 1B1: AMG 160 Monotherapy 0.3 mg eIV2-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.9 mg eIV3-2d-Inf | Part 1B1: AMG 160 Monotherapy 0.9 mg eIV3-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.6 mg eIV4-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.3 mg eIV5-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.3 mg eIV5-5d-Inf | Part 1B2: AMG 160 Monotherapy 0.09 mg eIVJC1-3d-Inf | Part 1B2: AMG 160 Monotherapy 0.3 mg eIVJC2-3d-Inf | Part 1: AMG Monotherapy DE (Dose F) | Part 2: AMG 160 + Pembrolizumab 0.03 mg SDPC1 | Part 2: AMG 160 + Pembrolizumab 0.3 mg SDPC2 | Part 2: AMG 160 + Pembrolizumab 0.15 mg eIVPC3-3d-Inf | Part 2: AMG 160 + Pembrolizumab 0.3 mg eIVPC4-3d-Inf | Part 2: AMG 160 + Pembrolizumab 0.15 mg eIVPC3-3d-Inf D-RP2D | Part 3: AMG 160 With CRS Prophylaxis 0.9 mg SDEC1 | Part 3: AMG 160 With CRS Prophylaxis 0.3 mg eIVEC1-3d-Inf | Part 4: AMG 160 Monotherapy 0.3 mg 24HR | Part 5: AMG 160 Monotherapy 0.3 mg 8HR |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Objective Response (OR) Rate- Parts 1, 2, 3, 4, and 5 | 0 (0.00 to 84.19) | 0 (0.00 to 84.19) | — | 100 (2.50 to 100.00) | 20 (0.51 to 71.64) | 0 (0.00 to 84.19) | 0 (0.00 to 84.19) | 0 (0.00 to 70.76) | 0 (0.00 to 97.50) | 0 (0.00 to 70.76) | 0 (0.00 to 84.19) | 0 (0.00 to 97.50) | 50 (1.26 to 98.74) | 0 (0.00 to 97.50) | — | 100 (2.50 to 100.00) | 50 (1.26 to 98.74) | 0 (0.00 to 70.76) | 0 (0.00 to 70.76) | 0 (0.00 to 70.76) | 7.4 (0.91 to 24.29) | 0 (0.00 to 52.18) | 0 (0.00 to 70.76) | 0 (0.00 to 84.19) | 25 (0.63 to 80.59) | 0 (0.00 to 84.19) | 0 (0.00 to 84.19) | 33.3 (0.84 to 90.57) | 16.7 (2.09 to 48.41) | 0 (0.00 to 30.85) |
A PSA response (PSA 30) is defined as a ≥ 30% reduction from the baseline PSA, (PSA 50) is defined as a ≥ 50% reduction from the baseline PSA, (PSA 70) is defined as a ≥ 70% reduction from the baseline PSA, and (PSA 90) is defined as a ≥ 90% reduction from the baseline PSA. PSA response must be confirmed by a second consecutive value ≥ 3 weeks later.
| Percentage of Participants | Part 1A: AMG 160 Monotherapy 0.003 mg | Part 1A: AMG 160 Monotherapy 0.01 mg | Part 1A: AMG 160 Monotherapy 0.03 mg | Part 1A: AMG 160 Monotherapy 0.03 mg SD1 | Part 1A: AMG 160 Monotherapy 0.09 mg SD2 | Part 1A: AMG 160 Monotherapy 0.3 mg SD3 | Part 1A: AMG 160 Monotherapy 0.9 mg SD4 | Part 1A: AMG 160 Monotherapy 0.9 mg SD5 | Part 1A: AMG 160 0.9 mg + Tocilizumab SD6 | Part 1A: AMG 160 Monotherapy 0.9 mg SD7 | Part 1B1: AMG 160 Monotherapy 0.09 mg eIV1-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.3 mg eIV2-2d-Inf | Part 1B1: AMG 160 Monotherapy 0.3 mg eIV2-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.9 mg eIV3-2d-Inf | Part 1B1: AMG 160 Monotherapy 0.9 mg eIV3-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.6 mg eIV4-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.3 mg eIV5-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.3 mg eIV5-5d-Inf | Part 1B2: AMG 160 Monotherapy 0.09 mg eIVJC1-3d-Inf | Part 1B2: AMG 160 Monotherapy 0.3 mg eIVJC2-3d-Inf | Part 1: AMG Monotherapy DE (Dose F) | Part 2: AMG 160 + Pembrolizumab 0.03 mg SDPC1 | Part 2: AMG 160 + Pembrolizumab 0.3 mg SDPC2 | Part 2: AMG 160 + Pembrolizumab 0.15 mg eIVPC3-3d-Inf | Part 2: AMG 160 + Pembrolizumab 0.3 mg eIVPC4-3d-Inf | Part 2: AMG 160 + Pembrolizumab 0.15 mg eIVPC3-3d-Inf D-RP2D | Part 3: AMG 160 With CRS Prophylaxis 0.9 mg SDEC1 | Part 3: AMG 160 With CRS Prophylaxis 0.3 mg eIVEC1-3d-Inf | Part 4: AMG 160 Monotherapy 0.3 mg 24HR | Part 5: AMG 160 Monotherapy 0.3 mg 8HR |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PSA 30 | 0 (0.00 to 70.76) | 0 (0.00 to 60.64) | 100 (2.50 to 100.00) | 33.3 (0.84 to 90.57) | 16.7 (0.42 to 64.12) | 50 (6.76 to 93.24) | 50 (6.76 to 93.24) | 25 (0.63 to 80.59) | 33.3 (0.84 to 90.57) | 25 (0.63 to 80.59) | 20 (0.51 to 71.64) | 50 (6.76 to 93.24) | 66.7 (9.43 to 99.16) | 100 (15.81 to 100.00) | 100 (2.50 to 100.00) | 100 (39.76 to 100.00) | 75 (19.41 to 99.37) | 16.7 (0.42 to 64.12) | 50 (6.76 to 93.24) | 57.1 (18.41 to 90.10) | 39.3 (26.50 to 53.25) | 16.7 (0.42 to 64.12) | 33.3 (0.84 to 90.57) | 40 (5.27 to 85.34) | 14.3 (0.36 to 57.87) | 0 (0.00 to 70.76) | 33.3 (0.84 to 90.57) | 33.3 (0.84 to 90.57) | 38.5 (20.23 to 59.43) | 38.1 (18.11 to 64.56) |
| PSA 50 | 0 (0.00 to 70.76) | 0 (0.00 to 60.64) | 100 (2.50 to 100.00) | 0 (0.00 to 70.76) | 16.7 (0.42 to 64.12) | 25 (0.63 to 80.59) | 25 (0.63 to 80.59) | 0 (0.00 to 60.24) | 33.3 (0.84 to 90.57) | 25 (0.63 to 80.59) | 20 (0.51 to 71.64) | 50 (6.76 to 93.24) | 66.7 (9.43 to 99.16) | 100 (15.81 to 100.00) | 100 (2.50 to 100.00) | 75 (19.41 to 99.37) | 75 (19.41 to 99.37) | 16.7 (0.42 to 64.12) | 25 (0.63 to 80.59) | 42.9 (9.90 to 81.59) | 30.4 (18.78 to 44.10) | 16.7 (0.42 to 64.12) | 0 (0.00 to 70.76) | 20 (0.51 to 71.64) | 14.3 (0.36 to 57.87) | 0 (0.00 to 70.76) | 33.3 (0.84 to 90.57) | 33.3 (0.84 to 90.57) | 34.6 (17.21 to 55.67) | 19.0 (5.45 to 41.91) |
| PSA 70 | 0 (0.00 to 70.76) | 0 (0.00 to 60.64) | 0 (0.00 to 97.50) | 0 (0.00 to 70.76) | 16.7 (0.42 to 64.12) | 0 (0.00 to 60.24) | 25 (0.63 to 80.59) | 0 (0.00 to 60.24) | 33.3 (0.84 to 90.57) | 0 (0.00 to 60.24) | 20 (0.51 to 71.64) | 50 (6.76 to 93.24) | 33.3 (0.84 to 90.57) | 100 (15.81 to 100.00) | 100 (2.50 to 100.00) | 75 (19.41 to 99.37) | 50 (6.76 to 93.24) | 16.7 (0.42 to 64.12) | 0 (0.00 to 60.24) | 14.3 (0.36 to 57.87) | 21.4 (11.59 to 34.44) | 16.7 (0.42 to 64.12) | 0 (0.00 to 70.76) | 20 (0.51 to 71.64) | 0 (0.00 to 40.96) | 0 (0.00 to 70.76) | 33.3 (0.84 to 90.57) | 33.3 (0.84 to 90.57) | 30.8 (14.33 to 51.79) | 19.0 (5.45 to 41.91) |
| PSA 90 | 0 (0.00 to 70.76) | 0 (0.00 to 60.64) | 0 (0.00 to 97.50) | 0 (0.00 to 70.76) | 16.7 (0.42 to 64.12) | 0 (0.00 to 60.24) | 0 (0.00 to 60.24) | 0 (0.00 to 60.24) | 33.3 (0.84 to 90.57) | 0 (0.00 to 60.24) | 0 (0.00 to 52.18) | 25 (0.63 to 93.24) | 33.3 (0.84 to 80.59) | 100 (15.81 to 100.00) | 0 (0.00 to 97.50) | 50 (6.76 to 93.24) | 25 (0.63 to 80.59) | 16.7 (0.42 to 64.12) | 0 (0.00 to 60.24) | 0 (0.00 to 40.96) | 5.4 (1.12 to 14.87) | 0 (0.00 to 45.93) | 0 (0.00 to 70.76) | 20 (0.51 to 71.64) | 0 (0.00 to 40.96) | 0 (0.00 to 70.76) | 0 (0.00 to 70.76) | 0 (0.00 to 70.76) | 15.4 (4.36 to 34.87) | 9.5 (1.17 to 30.83) |
DOR is defined as the time from the date of an initial objective response per RECIST 1.1 to the earlier of progression or death. Participants who had not ended their response at the time of analysis had DOR censored at their last evaluable tumor assessment.
| Months | Part 1A: AMG 160 Monotherapy 0.003 mg | Part 1A: AMG 160 Monotherapy 0.01 mg | Part 1A: AMG 160 Monotherapy 0.03 mg | Part 1A: AMG 160 Monotherapy 0.03 mg SD1 | Part 1A: AMG 160 Monotherapy 0.09 mg SD2 | Part 1A: AMG 160 Monotherapy 0.3 mg SD3 | Part 1A: AMG 160 Monotherapy 0.9 mg SD4 | Part 1A: AMG 160 Monotherapy 0.9 mg SD5 | Part 1A: AMG 160 0.9 mg + Tocilizumab SD6 | Part 1A: AMG 160 Monotherapy 0.9 mg SD7 | Part 1B1: AMG 160 Monotherapy 0.09 mg eIV1-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.3 mg eIV2-2d-Inf | Part 1B1: AMG 160 Monotherapy 0.3 mg eIV2-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.9 mg eIV3-2d-Inf | Part 1B1: AMG 160 Monotherapy 0.9 mg eIV3-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.6 mg eIV4-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.3 mg eIV5-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.3 mg eIV5-5d-Inf | Part 1B2: AMG 160 Monotherapy 0.09 mg eIVJC1-3d-Inf | Part 1B2: AMG 160 Monotherapy 0.3 mg eIVJC2-3d-Inf | Part 1: AMG Monotherapy DE (Dose F) | Part 2: AMG 160 + Pembrolizumab 0.03 mg SDPC1 | Part 2: AMG 160 + Pembrolizumab 0.3 mg SDPC2 | Part 2: AMG 160 + Pembrolizumab 0.15 mg eIVPC3-3d-Inf | Part 2: AMG 160 + Pembrolizumab 0.3 mg eIVPC4-3d-Inf | Part 2: AMG 160 + Pembrolizumab 0.15 mg eIVPC3-3d-Inf D-RP2D | Part 3: AMG 160 With CRS Prophylaxis 0.9 mg SDEC1 | Part 3: AMG 160 With CRS Prophylaxis 0.3 mg eIVEC1-3d-Inf | Part 4: AMG 160 Monotherapy 0.3 mg 24HR | Part 5: AMG 160 Monotherapy 0.3 mg 8HR |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Duration of Response (DOR)-RECIST 1.1- Parts 1, 2, 3, 4, and 5 | — | — | — | 5.62 (NA to NA) | 8.57 (NA to NA) | — | — | — | — | — | — | — | NA (NA to NA) | — | — | NA (NA to NA) | NA (NA to NA) | — | — | — | 5.19 (3.81 to NA) | — | — | — | NA (NA to NA) | — | — | NA (NA to NA) | NA (NA to NA) | — |
PSA DOR is defined as the time from the date of an initial PSA response (PSA 50) to the earlier of PSA progression or death. Subjects who have not ended their response at the time of analysis will have PSA DOR censored on the date of their last PSA measurement. This endpoint only applies to subjects with a PSA response (PSA 50).
| Months | Part 1A: AMG 160 Monotherapy 0.003 mg | Part 1A: AMG 160 Monotherapy 0.01 mg | Part 1A: AMG 160 Monotherapy 0.03 mg | Part 1A: AMG 160 Monotherapy 0.03 mg SD1 | Part 1A: AMG 160 Monotherapy 0.09 mg SD2 | Part 1A: AMG 160 Monotherapy 0.3 mg SD3 | Part 1A: AMG 160 Monotherapy 0.9 mg SD4 | Part 1A: AMG 160 Monotherapy 0.9 mg SD5 | Part 1A: AMG 160 0.9 mg + Tocilizumab SD6 | Part 1A: AMG 160 Monotherapy 0.9 mg SD7 | Part 1B1: AMG 160 Monotherapy 0.09 mg eIV1-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.3 mg eIV2-2d-Inf | Part 1B1: AMG 160 Monotherapy 0.3 mg eIV2-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.9 mg eIV3-2d-Inf | Part 1B1: AMG 160 Monotherapy 0.9 mg eIV3-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.6 mg eIV4-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.3 mg eIV5-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.3 mg eIV5-5d-Inf | Part 1B2: AMG 160 Monotherapy 0.09 mg eIVJC1-3d-Inf | Part 1B2: AMG 160 Monotherapy 0.3 mg eIVJC2-3d-Inf | Part 1: AMG Monotherapy DE (Dose F) | Part 2: AMG 160 + Pembrolizumab 0.03 mg SDPC1 | Part 2: AMG 160 + Pembrolizumab 0.3 mg SDPC2 | Part 2: AMG 160 + Pembrolizumab 0.15 mg eIVPC3-3d-Inf | Part 2: AMG 160 + Pembrolizumab 0.3 mg eIVPC4-3d-Inf | Part 2: AMG 160 + Pembrolizumab 0.15 mg eIVPC3-3d-Inf D-RP2D | Part 3: AMG 160 With CRS Prophylaxis 0.9 mg SDEC1 | Part 3: AMG 160 With CRS Prophylaxis 0.3 mg eIVEC1-3d-Inf | Part 4: AMG 160 Monotherapy 0.3 mg 24HR | Part 5: AMG 160 Monotherapy 0.3 mg 8HR |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Duration of PSA Response- Parts 1, 2, 3, 4, and 5 | — | — | 1.87 (NA to NA) | — | 25.33 (NA to NA) | 2.14 (NA to NA) | 2.79 (NA to NA) | — | 0.99 (NA to NA) | 1.87 (NA to NA) | 2.83 (NA to NA) | 2.79 (1.87 to NA) | 3.30 (1.97 to NA) | 5.03 (4.53 to NA) | 0.99 (NA to NA) | 2.20 (0.99 to NA) | 1.84 (0.99 to NA) | 1.87 (NA to NA) | 1.91 (NA to NA) | 1.15 (0.95 to NA) | 1.91 (0.95 to 3.71) | 4.96 (NA to NA) | — | 4.86 (NA to NA) | 0.95 (NA to NA) | — | 1.81 (NA to NA) | 1.87 (NA to NA) | 2.79 (0.95 to 7.66) | 3.29 (2.23 to NA) |
A Gallium PSMA-11 response is a ≥50% reduction from baseline in the maximum standardized uptake value (SUV) using 68Gallium (68Ga)-prostate-specific membrane antigen (PSMA)-11 positron emission tomography (PET)/computed tomography (CT).
| Percentage of Participants | Part 1A: AMG 160 Monotherapy 0.003 mg | Part 1A: AMG 160 Monotherapy 0.01 mg | Part 1A: AMG 160 Monotherapy 0.03 mg | Part 1A: AMG 160 Monotherapy 0.03 mg SD1 | Part 1A: AMG 160 Monotherapy 0.09 mg SD2 | Part 1A: AMG 160 Monotherapy 0.3 mg SD3 | Part 1A: AMG 160 Monotherapy 0.9 mg SD4 | Part 1A: AMG 160 Monotherapy 0.9 mg SD5 | Part 1A: AMG 160 0.9 mg + Tocilizumab SD6 | Part 1A: AMG 160 Monotherapy 0.9 mg SD7 | Part 1B1: AMG 160 Monotherapy 0.09 mg eIV1-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.3 mg eIV2-2d-Inf | Part 1B1: AMG 160 Monotherapy 0.3 mg eIV2-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.9 mg eIV3-2d-Inf | Part 1B1: AMG 160 Monotherapy 0.9 mg eIV3-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.6 mg eIV4-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.3 mg eIV5-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.3 mg eIV5-5d-Inf | Part 1B2: AMG 160 Monotherapy 0.09 mg eIVJC1-3d-Inf | Part 1B2: AMG 160 Monotherapy 0.3 mg eIVJC2-3d-Inf | Part 1: AMG Monotherapy DE (Dose F) | Part 2: AMG 160 + Pembrolizumab 0.03 mg SDPC1 | Part 2: AMG 160 + Pembrolizumab 0.3 mg SDPC2 | Part 2: AMG 160 + Pembrolizumab 0.15 mg eIVPC3-3d-Inf | Part 2: AMG 160 + Pembrolizumab 0.3 mg eIVPC4-3d-Inf | Part 2: AMG 160 + Pembrolizumab 0.15 mg eIVPC3-3d-Inf D-RP2D | Part 3: AMG 160 With CRS Prophylaxis 0.9 mg SDEC1 | Part 3: AMG 160 With CRS Prophylaxis 0.3 mg eIVEC1-3d-Inf |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Percentage of Participants With 68Gallium (68Ga)-Prostate-specific Membrane Antigen (PSMA) Response Parts 1, 2, and 3 | 0 (0.00 to 84.19) | 0 (0.00 to 97.50) | 0 (0.00 to 97.50) | 50 (1.26 to 98.74) | 33.3 (0.84 to 90.57) | 0 (0.00 to 84.19) | 0 (NA to NA) | 50 (1.26 to 98.74) | 0 (0.00 to 97.50) | 0 (0.00 to 60.24) | 0 (0.00 to 45.93) | 0 (0.00 to 97.50) | 33.3 (0.84 to 90.57) | 50 (1.26 to 98.74) | 0 (NA to NA) | 0 (NA to NA) | 50 (1.26 to 98.74) | 0 (0.00 to 97.50) | 0 (NA to NA) | 0 (NA to NA) | 29.5 (16.76 to 45.20) | 33.3 (4.33 to 77.72) | 0 (0.00 to 97.50) | 33.3 (0.84 to 90.57) | 25 (0.63 to 80.59) | 0 (0.00 to 84.19) | 0 (0.00 to 70.76) | 0 (0.00 to 70.76) |
A FDG PET response is a ≥50% reduction from baseline in the maximum SUV using 18F-FDG PET/CT.
| Percentage of Participants | Part 1A: AMG 160 Monotherapy 0.003 mg | Part 1A: AMG 160 Monotherapy 0.01 mg | Part 1A: AMG 160 Monotherapy 0.03 mg | Part 1A: AMG 160 Monotherapy 0.03 mg SD1 | Part 1A: AMG 160 Monotherapy 0.09 mg SD2 | Part 1A: AMG 160 Monotherapy 0.3 mg SD3 | Part 1A: AMG 160 Monotherapy 0.9 mg SD4 | Part 1A: AMG 160 Monotherapy 0.9 mg SD5 | Part 1A: AMG 160 0.9 mg + Tocilizumab SD6 | Part 1A: AMG 160 Monotherapy 0.9 mg SD7 | Part 1B1: AMG 160 Monotherapy 0.09 mg eIV1-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.3 mg eIV2-2d-Inf | Part 1B1: AMG 160 Monotherapy 0.3 mg eIV2-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.9 mg eIV3-2d-Inf | Part 1B1: AMG 160 Monotherapy 0.9 mg eIV3-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.6 mg eIV4-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.3 mg eIV5-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.3 mg eIV5-5d-Inf | Part 1B2: AMG 160 Monotherapy 0.09 mg eIVJC1-3d-Inf | Part 1B2: AMG 160 Monotherapy 0.3 mg eIVJC2-3d-Inf | Part 1: AMG Monotherapy DE (Dose F) | Part 2: AMG 160 + Pembrolizumab 0.03 mg SDPC1 | Part 2: AMG 160 + Pembrolizumab 0.3 mg SDPC2 | Part 2: AMG 160 + Pembrolizumab 0.15 mg eIVPC3-3d-Inf | Part 2: AMG 160 + Pembrolizumab 0.3 mg eIVPC4-3d-Inf | Part 2: AMG 160 + Pembrolizumab 0.15 mg eIVPC3-3d-Inf D-RP2D | Part 3: AMG 160 With CRS Prophylaxis 0.9 mg SDEC1 | Part 3: AMG 160 With CRS Prophylaxis 0.3 mg eIVEC1-3d-Inf |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Percentage of Participants With F-fluorodeoxyglucose (FDG) Response- Parts 1, 2, and 3 | 0 (0.00 to 84.19) | 0 (0.00 to 84.19) | 0 (0.00 to 97.50) | 0 (0.00 to 84.19) | 0 (0.00 to 60.24) | 0 (0.00 to 84.19) | 0 (0.00 to 97.50) | 0 (0.00 to 97.50) | 0 (0.00 to 97.50) | 0 (0.00 to 60.24) | 0 (0.00 to 45.93) | 0 (0.00 to 97.50) | 0 (0.00 to 70.76) | 0 (0.00 to 84.19) | 0 (NA to NA) | 0 (NA to NA) | 0 (0.00 to 84.19) | 0 (0.00 to 97.50) | 0 (NA to NA) | 0 (NA to NA) | 7.7 (1.62 to 20.87) | 0 (0.00 to 52.18) | 0 (0.00 to 97.50) | 0 (0.00 to 70.76) | 0 (0.00 to 45.93) | 0 (0.00 to 84.19) | 0 (0.00 to 70.76) | 0 (0.00 to 70.76) |
Time to radiographic progression is defined as the time from study Day 1 until the first documentation of radiographic disease progression in the absence of subsequent anticancer therapy. Time to radiographic progression will be censored at the last evaluable post-baseline tumor assessment prior to subsequent anti-cancer therapy; otherwise, at study Day 1.
| Months | Part 1A: AMG 160 Monotherapy 0.003 mg | Part 1A: AMG 160 Monotherapy 0.01 mg | Part 1A: AMG 160 Monotherapy 0.03 mg | Part 1A: AMG 160 Monotherapy 0.03 mg SD1 | Part 1A: AMG 160 Monotherapy 0.09 mg SD2 | Part 1A: AMG 160 Monotherapy 0.3 mg SD3 | Part 1A: AMG 160 Monotherapy 0.9 mg SD4 | Part 1A: AMG 160 Monotherapy 0.9 mg SD5 | Part 1A: AMG 160 0.9 mg + Tocilizumab SD6 | Part 1A: AMG 160 Monotherapy 0.9 mg SD7 | Part 1B1: AMG 160 Monotherapy 0.09 mg eIV1-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.3 mg eIV2-2d-Inf | Part 1B1: AMG 160 Monotherapy 0.3 mg eIV2-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.9 mg eIV3-2d-Inf | Part 1B1: AMG 160 Monotherapy 0.9 mg eIV3-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.6 mg eIV4-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.3 mg eIV5-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.3 mg eIV5-5d-Inf | Part 1B2: AMG 160 Monotherapy 0.09 mg eIVJC1-3d-Inf | Part 1B2: AMG 160 Monotherapy 0.3 mg eIVJC2-3d-Inf | Part 1: AMG Monotherapy DE (Dose F) | Part 2: AMG 160 + Pembrolizumab 0.03 mg SDPC1 | Part 2: AMG 160 + Pembrolizumab 0.3 mg SDPC2 | Part 2: AMG 160 + Pembrolizumab 0.15 mg eIVPC3-3d-Inf | Part 2: AMG 160 + Pembrolizumab 0.3 mg eIVPC4-3d-Inf | Part 2: AMG 160 + Pembrolizumab 0.15 mg eIVPC3-3d-Inf D-RP2D | Part 3: AMG 160 With CRS Prophylaxis 0.9 mg SDEC1 | Part 3: AMG 160 With CRS Prophylaxis 0.3 mg eIVEC1-3d-Inf | Part 4: AMG 160 Monotherapy 0.3 mg 24HR | Part 5: AMG 160 Monotherapy 0.3 mg 8HR |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Time to Progression (Radiographic)- Parts 1, 2, 3, 4, and 5 | NA (1.74 to NA) | 5.01 (1.64 to NA) | NA (NA to NA) | 13.77 (NA to NA) | 2.07 (0.49 to NA) | 3.81 (1.64 to NA) | 2.83 (1.87 to NA) | 2.69 (1.58 to NA) | 3.53 (1.71 to NA) | 2.00 (1.71 to NA) | 10.84 (0.89 to NA) | NA (1.87 to NA) | 5.95 (3.75 to NA) | 8.38 (NA to NA) | NA (NA to NA) | 8.34 (NA to NA) | NA (NA to NA) | 5.19 (1.87 to NA) | 2.74 (0.46 to NA) | 3.66 (1.71 to NA) | 3.58 (1.97 to 5.39) | 2.07 (1.81 to NA) | 1.71 (1.64 to NA) | 8.18 (1.84 to NA) | NA (1.94 to NA) | 1.68 (NA to NA) | 2.33 (1.15 to NA) | 1.81 (1.64 to NA) | 5.39 (3.68 to 11.07) | 5.65 (2.33 to 8.57) |
Time to PSA progression is defined as the interval from study Day 1 to PSA progression; otherwise, time to PSA progression is censored on the date of the last PSA measurement. If a participant has no baseline or no post-baseline PSA measurement, time to PSA progression will be censored at study Day 1.
| Months | Part 1A: AMG 160 Monotherapy 0.003 mg | Part 1A: AMG 160 Monotherapy 0.01 mg | Part 1A: AMG 160 Monotherapy 0.03 mg | Part 1A: AMG 160 Monotherapy 0.03 mg SD1 | Part 1A: AMG 160 Monotherapy 0.09 mg SD2 | Part 1A: AMG 160 Monotherapy 0.3 mg SD3 | Part 1A: AMG 160 Monotherapy 0.9 mg SD4 | Part 1A: AMG 160 Monotherapy 0.9 mg SD5 | Part 1A: AMG 160 0.9 mg + Tocilizumab SD6 | Part 1A: AMG 160 Monotherapy 0.9 mg SD7 | Part 1B1: AMG 160 Monotherapy 0.09 mg eIV1-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.3 mg eIV2-2d-Inf | Part 1B1: AMG 160 Monotherapy 0.3 mg eIV2-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.9 mg eIV3-2d-Inf | Part 1B1: AMG 160 Monotherapy 0.9 mg eIV3-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.6 mg eIV4-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.3 mg eIV5-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.3 mg eIV5-5d-Inf | Part 1B2: AMG 160 Monotherapy 0.09 mg eIVJC1-3d-Inf | Part 1B2: AMG 160 Monotherapy 0.3 mg eIVJC2-3d-Inf | Part 1: AMG Monotherapy DE (Dose F) | Part 2: AMG 160 + Pembrolizumab 0.03 mg SDPC1 | Part 2: AMG 160 + Pembrolizumab 0.3 mg SDPC2 | Part 2: AMG 160 + Pembrolizumab 0.15 mg eIVPC3-3d-Inf | Part 2: AMG 160 + Pembrolizumab 0.3 mg eIVPC4-3d-Inf | Part 2: AMG 160 + Pembrolizumab 0.15 mg eIVPC3-3d-Inf D-RP2D | Part 3: AMG 160 With CRS Prophylaxis 0.9 mg SDEC1 | Part 3: AMG 160 With CRS Prophylaxis 0.3 mg eIVEC1-3d-Inf | Part 4: AMG 160 Monotherapy 0.3 mg 24HR | Part 5: AMG 160 Monotherapy 0.3 mg 8HR |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Time to Progression (PSA)- Parts 1, 2, 3, 4, and 5 | 2.79 (NA to NA) | 4.37 (2.53 to NA) | 2.79 (NA to NA) | 3.48 (3.02 to NA) | 3.14 (2.10 to NA) | 2.23 (1.87 to NA) | 3.71 (2.14 to NA) | 2.48 (1.84 to NA) | NA (1.87 to NA) | 3.02 (2.99 to NA) | 3.68 (3.06 to NA) | 4.83 (3.02 to NA) | 3.02 (2.99 to NA) | 6.70 (4.99 to NA) | 2.10 (NA to NA) | 3.48 (2.14 to NA) | 3.70 (2.10 to NA) | 3.06 (1.22 to NA) | 2.07 (NA to NA) | 2.99 (2.10 to NA) | 3.02 (3.02 to 4.86) | NA (2.07 to NA) | 1.87 (1.51 to NA) | 6.01 (2.63 to NA) | 2.10 (2.10 to NA) | NA (NA to NA) | 2.72 (2.40 to NA) | 2.10 (NA to NA) | 3.94 (2.14 to 5.55) | 3.02 (2.10 to 6.70) |
Radiographic progression free survival (rPFS) is defined as the interval from study day 1 to the earlier of a radiographic progression or death from any cause; otherwise, rPFS is censored at the last evaluable tumor assessment date. If a subject has no post-baseline radiographic tumor assessment and a vital status of alive or unknown, rPFS will be censored at study day 1.
| Months | Part 1A: AMG 160 Monotherapy 0.003 mg | Part 1A: AMG 160 Monotherapy 0.01 mg | Part 1A: AMG 160 Monotherapy 0.03 mg | Part 1A: AMG 160 Monotherapy 0.03 mg SD1 | Part 1A: AMG 160 Monotherapy 0.09 mg SD2 | Part 1A: AMG 160 Monotherapy 0.3 mg SD3 | Part 1A: AMG 160 Monotherapy 0.9 mg SD4 | Part 1A: AMG 160 Monotherapy 0.9 mg SD5 | Part 1A: AMG 160 0.9 mg + Tocilizumab SD6 | Part 1A: AMG 160 Monotherapy 0.9 mg SD7 | Part 1B1: AMG 160 Monotherapy 0.09 mg eIV1-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.3 mg eIV2-2d-Inf | Part 1B1: AMG 160 Monotherapy 0.3 mg eIV2-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.9 mg eIV3-2d-Inf | Part 1B1: AMG 160 Monotherapy 0.9 mg eIV3-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.6 mg eIV4-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.3 mg eIV5-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.3 mg eIV5-5d-Inf | Part 1B2: AMG 160 Monotherapy 0.09 mg eIVJC1-3d-Inf | Part 1B2: AMG 160 Monotherapy 0.3 mg eIVJC2-3d-Inf | Part 1: AMG Monotherapy DE (Dose F) | Part 2: AMG 160 + Pembrolizumab 0.03 mg SDPC1 | Part 2: AMG 160 + Pembrolizumab 0.3 mg SDPC2 | Part 2: AMG 160 + Pembrolizumab 0.15 mg eIVPC3-3d-Inf | Part 2: AMG 160 + Pembrolizumab 0.3 mg eIVPC4-3d-Inf | Part 2: AMG 160 + Pembrolizumab 0.15 mg eIVPC3-3d-Inf D-RP2D | Part 3: AMG 160 With CRS Prophylaxis 0.9 mg SDEC1 | Part 3: AMG 160 With CRS Prophylaxis 0.3 mg eIVEC1-3d-Inf | Part 4: AMG 160 Monotherapy 0.3 mg 24HR | Part 5: AMG 160 Monotherapy 0.3 mg 8HR |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Progression Free Survival (Radiographic)- Parts 1, 2, 3, 4, and 5 | 1.74 (1.41 to NA) | 5.01 (1.64 to NA) | NA (NA to NA) | 11.43 (1.45 to NA) | 2.07 (0.49 to NA) | 4.35 (1.64 to NA) | 2.83 (1.87 to NA) | 2.69 (1.58 to NA) | 2.23 (1.71 to NA) | 2.00 (1.71 to NA) | 10.84 (0.89 to NA) | NA (1.87 to NA) | 5.95 (3.75 to NA) | 8.38 (NA to NA) | NA (NA to NA) | 8.34 (NA to NA) | NA (6.90 to NA) | 4.47 (1.87 to NA) | 2.74 (0.46 to NA) | 3.66 (1.71 to NA) | 3.71 (1.97 to 5.36) | 2.89 (1.81 to NA) | 1.71 (1.64 to NA) | 8.18 (1.84 to NA) | NA (1.94 to NA) | 0.89 (0.10 to NA) | 2.40 (1.15 to NA) | 1.81 (1.64 to NA) | 5.39 (3.61 to 11.07) | 5.62 (3.38 to 8.57) |
PSA PFS is defined as the interval from study day 1 to the earlier of a PSA progression or death from any cause; otherwise, PSA PFS is censored on the date of the last PSA measurement. If a subject has no baseline or no post-baseline PSA measurement and a vital status of alive or unknown, PSA PFS will be censored at study day 1.
| Months | Part 1A: AMG 160 Monotherapy 0.003 mg | Part 1A: AMG 160 Monotherapy 0.01 mg | Part 1A: AMG 160 Monotherapy 0.03 mg | Part 1A: AMG 160 Monotherapy 0.03 mg SD1 | Part 1A: AMG 160 Monotherapy 0.09 mg SD2 | Part 1A: AMG 160 Monotherapy 0.3 mg SD3 | Part 1A: AMG 160 Monotherapy 0.9 mg SD4 | Part 1A: AMG 160 Monotherapy 0.9 mg SD5 | Part 1A: AMG 160 0.9 mg + Tocilizumab SD6 | Part 1A: AMG 160 Monotherapy 0.9 mg SD7 | Part 1B1: AMG 160 Monotherapy 0.09 mg eIV1-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.3 mg eIV2-2d-Inf | Part 1B1: AMG 160 Monotherapy 0.3 mg eIV2-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.9 mg eIV3-2d-Inf | Part 1B1: AMG 160 Monotherapy 0.9 mg eIV3-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.6 mg eIV4-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.3 mg eIV5-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.3 mg eIV5-5d-Inf | Part 1B2: AMG 160 Monotherapy 0.09 mg eIVJC1-3d-Inf | Part 1B2: AMG 160 Monotherapy 0.3 mg eIVJC2-3d-Inf | Part 1: AMG Monotherapy DE (Dose F) | Part 2: AMG 160 + Pembrolizumab 0.03 mg SDPC1 | Part 2: AMG 160 + Pembrolizumab 0.3 mg SDPC2 | Part 2: AMG 160 + Pembrolizumab 0.15 mg eIVPC3-3d-Inf | Part 2: AMG 160 + Pembrolizumab 0.3 mg eIVPC4-3d-Inf | Part 2: AMG 160 + Pembrolizumab 0.15 mg eIVPC3-3d-Inf D-RP2D | Part 3: AMG 160 With CRS Prophylaxis 0.9 mg SDEC1 | Part 3: AMG 160 With CRS Prophylaxis 0.3 mg eIVEC1-3d-Inf | Part 4: AMG 160 Monotherapy 0.3 mg 24HR | Part 5: AMG 160 Monotherapy 0.3 mg 8HR |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Progression Free Survival (PSA)- Parts 1, 2, 3, 4, and 5 | 2.79 (1.41 to NA) | 3.60 (2.53 to NA) | 2.79 (NA to NA) | 3.02 (1.45 to NA) | 3.14 (0.72 to NA) | 2.23 (1.87 to NA) | 3.25 (2.14 to NA) | 2.48 (1.84 to NA) | 2.23 (1.87 to NA) | 4.75 (2.99 to NA) | 3.98 (3.06 to NA) | 4.83 (3.02 to NA) | 3.02 (2.99 to NA) | 5.85 (4.99 to NA) | 2.10 (NA to NA) | 3.63 (2.14 to NA) | 3.70 (2.10 to NA) | 3.06 (1.22 to NA) | 3.29 (2.07 to NA) | 3.01 (2.10 to NA) | 3.58 (3.02 to 4.90) | 5.63 (2.07 to NA) | 1.87 (1.51 to NA) | 8.54 (2.63 to NA) | 3.55 (2.10 to NA) | NA (0.10 to NA) | 2.56 (2.40 to NA) | 2.89 (2.10 to NA) | 3.98 (2.14 to 4.80) | 3.38 (2.10 to 7.03) |
Overall survival (OS) is defined as the time from the date of study Day 1 until death due to any cause.
| Months | Part 1A: AMG 160 Monotherapy 0.003 mg | Part 1A: AMG 160 Monotherapy 0.01 mg | Part 1A: AMG 160 Monotherapy 0.03 mg | Part 1A: AMG 160 Monotherapy 0.03 mg SD1 | Part 1A: AMG 160 Monotherapy 0.09 mg SD2 | Part 1A: AMG 160 Monotherapy 0.3 mg SD3 | Part 1A: AMG 160 Monotherapy 0.9 mg SD4 | Part 1A: AMG 160 Monotherapy 0.9 mg SD5 | Part 1A: AMG 160 0.9 mg + Tocilizumab SD6 | Part 1A: AMG 160 Monotherapy 0.9 mg SD7 | Part 1B1: AMG 160 Monotherapy 0.09 mg eIV1-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.3 mg eIV2-2d-Inf | Part 1B1: AMG 160 Monotherapy 0.3 mg eIV2-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.9 mg eIV3-2d-Inf | Part 1B1: AMG 160 Monotherapy 0.9 mg eIV3-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.6 mg eIV4-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.3 mg eIV5-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.3 mg eIV5-5d-Inf | Part 1B2: AMG 160 Monotherapy 0.09 mg eIVJC1-3d-Inf | Part 1B2: AMG 160 Monotherapy 0.3 mg eIVJC2-3d-Inf | Part 1: AMG Monotherapy DE (Dose F) | Part 2: AMG 160 + Pembrolizumab 0.03 mg SDPC1 | Part 2: AMG 160 + Pembrolizumab 0.3 mg SDPC2 | Part 2: AMG 160 + Pembrolizumab 0.15 mg eIVPC3-3d-Inf | Part 2: AMG 160 + Pembrolizumab 0.3 mg eIVPC4-3d-Inf | Part 2: AMG 160 + Pembrolizumab 0.15 mg eIVPC3-3d-Inf D-RP2D | Part 3: AMG 160 With CRS Prophylaxis 0.9 mg SDEC1 | Part 3: AMG 160 With CRS Prophylaxis 0.3 mg eIVEC1-3d-Inf | Part 4: AMG 160 Monotherapy 0.3 mg 24HR | Part 5: AMG 160 Monotherapy 0.3 mg 8HR |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Survival- Parts 1, 2, 3, 4, and 5 | 18.96 (1.41 to NA) | 11.32 (2.53 to NA) | NA (NA to NA) | 11.43 (1.45 to NA) | 26.51 (0.72 to NA) | NA (3.19 to NA) | 7.79 (2.79 to NA) | 8.28 (5.49 to NA) | 5.62 (2.23 to NA) | 7.75 (5.42 to NA) | 17.35 (4.60 to NA) | 18.14 (17.81 to NA) | 27.66 (13.44 to NA) | NA (4.99 to NA) | 8.08 (NA to NA) | NA (10.64 to NA) | 11.30 (6.90 to NA) | 6.51 (4.47 to NA) | 8.15 (4.50 to NA) | 16.39 (5.32 to NA) | 11.70 (8.64 to 14.59) | 6.90 (4.63 to NA) | 9.36 (6.57 to NA) | 22.67 (7.23 to NA) | 15.74 (4.04 to NA) | NA (0.10 to NA) | NA (2.40 to NA) | 4.96 (2.89 to NA) | 23.09 (10.58 to NA) | 13.24 (7.03 to NA) |
CTC0 is defined as reduction of CTCs \> 0 to 0 at any post-baseline measurement. CTC0 response is applicable only for participants with baseline CTC \> 0.
| Percentage of Participants | Part 1A: AMG 160 Monotherapy 0.003 mg | Part 1A: AMG 160 Monotherapy 0.01 mg | Part 1A: AMG 160 Monotherapy 0.03 mg | Part 1A: AMG 160 Monotherapy 0.03 mg SD1 | Part 1A: AMG 160 Monotherapy 0.09 mg SD2 | Part 1A: AMG 160 Monotherapy 0.3 mg SD3 | Part 1A: AMG 160 Monotherapy 0.9 mg SD4 | Part 1A: AMG 160 Monotherapy 0.9 mg SD5 | Part 1A: AMG 160 0.9 mg + Tocilizumab SD6 | Part 1A: AMG 160 Monotherapy 0.9 mg SD7 | Part 1B1: AMG 160 Monotherapy 0.09 mg eIV1-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.3 mg eIV2-2d-Inf | Part 1B1: AMG 160 Monotherapy 0.3 mg eIV2-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.9 mg eIV3-2d-Inf | Part 1B1: AMG 160 Monotherapy 0.9 mg eIV3-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.6 mg eIV4-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.3 mg eIV5-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.3 mg eIV5-5d-Inf | Part 1B2: AMG 160 Monotherapy 0.09 mg eIVJC1-3d-Inf | Part 1B2: AMG 160 Monotherapy 0.3 mg eIVJC2-3d-Inf | Part 1: AMG Monotherapy DE (Dose F) | Part 2: AMG 160 + Pembrolizumab 0.03 mg SDPC1 | Part 2: AMG 160 + Pembrolizumab 0.3 mg SDPC2 | Part 2: AMG 160 + Pembrolizumab 0.15 mg eIVPC3-3d-Inf | Part 2: AMG 160 + Pembrolizumab 0.3 mg eIVPC4-3d-Inf | Part 2: AMG 160 + Pembrolizumab 0.15 mg eIVPC3-3d-Inf D-RP2D | Part 3: AMG 160 With CRS Prophylaxis 0.9 mg SDEC1 | Part 3: AMG 160 With CRS Prophylaxis 0.3 mg eIVEC1-3d-Inf | Part 4: AMG 160 Monotherapy 0.3 mg 24HR | Part 5: AMG 160 Monotherapy 0.3 mg 8HR |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Percentage of Participants With Circulating Tumor Cell Response (CTC0)- Parts 1, 2, 3, 4, and 5 | 0 (0.00 to 84.19) | 0 (0.00 to 84.19) | — | 0 (0.00 to 84.19) | 100 (15.81 to 100.00) | 50 (1.26 to 98.74) | 66.7 (9.43 to 99.16) | 75 (19.41 to 99.37) | 33.3 (0.84 to 90.57) | 0 (0.00 to 60.24) | 20 (0.51 to 71.64) | 0 (0.00 to 84.19) | 100 (2.50 to 100.00) | — | — | 0 (0.00 to 97.50) | 66.7 (9.43 to 99.16) | 0 (0.00 to 70.76) | — | 0 (0.00 to 60.24) | 5.3 (0.13 to 26.03) | 20 (0.51 to 71.64) | 100 (2.50 to 100) | 100 (2.50 to 100) | 66.7 (9.43 to 99.16) | 0 (0.00 to 70.76) | 33.3 (0.84 to 90.57) | 0 (0.00 to 70.76) | 0 (0.00 to 21.80) | 0 (0.00 to 16.84) |
CTC conversion is defined as ≥ 5 CTCs/7.5 mL blood to ≤ 4 CTCs/7.5 mL blood at any post-baseline measurement. CTC conversion is applicable only for subjects with baseline CTC ≥ 5..
| Percentage of Participants | Part 1A: AMG 160 Monotherapy 0.003 mg | Part 1A: AMG 160 Monotherapy 0.01 mg | Part 1A: AMG 160 Monotherapy 0.03 mg | Part 1A: AMG 160 Monotherapy 0.03 mg SD1 | Part 1A: AMG 160 Monotherapy 0.09 mg SD2 | Part 1A: AMG 160 Monotherapy 0.3 mg SD3 | Part 1A: AMG 160 Monotherapy 0.9 mg SD4 | Part 1A: AMG 160 Monotherapy 0.9 mg SD5 | Part 1A: AMG 160 0.9 mg + Tocilizumab SD6 | Part 1A: AMG 160 Monotherapy 0.9 mg SD7 | Part 1B1: AMG 160 Monotherapy 0.09 mg eIV1-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.3 mg eIV2-2d-Inf | Part 1B1: AMG 160 Monotherapy 0.3 mg eIV2-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.9 mg eIV3-2d-Inf | Part 1B1: AMG 160 Monotherapy 0.9 mg eIV3-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.6 mg eIV4-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.3 mg eIV5-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.3 mg eIV5-5d-Inf | Part 1B2: AMG 160 Monotherapy 0.09 mg eIVJC1-3d-Inf | Part 1B2: AMG 160 Monotherapy 0.3 mg eIVJC2-3d-Inf | Part 1: AMG Monotherapy DE (Dose F) | Part 2: AMG 160 + Pembrolizumab 0.03 mg SDPC1 | Part 2: AMG 160 + Pembrolizumab 0.3 mg SDPC2 | Part 2: AMG 160 + Pembrolizumab 0.15 mg eIVPC3-3d-Inf | Part 2: AMG 160 + Pembrolizumab 0.3 mg eIVPC4-3d-Inf | Part 2: AMG 160 + Pembrolizumab 0.15 mg eIVPC3-3d-Inf D-RP2D | Part 3: AMG 160 With CRS Prophylaxis 0.9 mg SDEC1 | Part 3: AMG 160 With CRS Prophylaxis 0.3 mg eIVEC1-3d-Inf | Part 4: AMG 160 Monotherapy 0.3 mg 24HR | Part 5: AMG 160 Monotherapy 0.3 mg 8HR |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Percentage of Participants With CTC Conversion- Parts 1, 2, 3, 4, and 5 | 0 (0.00 to 84.19) | 0 (0.00 to 84.19) | — | 0 (0.00 to 84.19) | 100 (2.50 to 100.00) | 0 (0.00 to 97.50) | 100 (2.50 to 100.00) | 0 (0.00 to 97.50) | 33.3 (0.84 to 90.57) | 0 (0.00 to 84.19) | 0 (0.00 to 84.19) | 100 (2.50 to 100.00) | 100 (2.50 to 100.00) | — | — | 0 (0.00 to 97.50) | 100 (29.24 to 100.00) | 33.3 (0.84 to 90.57) | — | 33.3 (0.84 to 90.57) | 7.7 (0.19 to 36.03) | 20 (0.51 to 71.64) | — | 100 (2.50 to 100) | — | 100 (2.50 to 100.00) | 33.3 (0.84 to 90.57) | 33.3 (0.84 to 90.57) | 22.2 (2.81 to 60.01) | 38.5 (13.86 to 68.42) |
Time to SSE is defined as time from study day 1 to the first SSE. Otherwise, SSE is censored at the last dose date of AMG 160 or pembrolizumab or end of safety follow up date, whichever is later.
| Months | Part 1A: AMG 160 Monotherapy 0.003 mg | Part 1A: AMG 160 Monotherapy 0.01 mg | Part 1A: AMG 160 Monotherapy 0.03 mg | Part 1A: AMG 160 Monotherapy 0.03 mg SD1 | Part 1A: AMG 160 Monotherapy 0.09 mg SD2 | Part 1A: AMG 160 Monotherapy 0.3 mg SD3 | Part 1A: AMG 160 Monotherapy 0.9 mg SD4 | Part 1A: AMG 160 Monotherapy 0.9 mg SD5 | Part 1A: AMG 160 0.9 mg + Tocilizumab SD6 | Part 1A: AMG 160 Monotherapy 0.9 mg SD7 | Part 1B1: AMG 160 Monotherapy 0.09 mg eIV1-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.3 mg eIV2-2d-Inf | Part 1B1: AMG 160 Monotherapy 0.3 mg eIV2-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.9 mg eIV3-2d-Inf | Part 1B1: AMG 160 Monotherapy 0.9 mg eIV3-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.6 mg eIV4-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.3 mg eIV5-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.3 mg eIV5-5d-Inf | Part 1B2: AMG 160 Monotherapy 0.09 mg eIVJC1-3d-Inf | Part 1B2: AMG 160 Monotherapy 0.3 mg eIVJC2-3d-Inf | Part 1: AMG Monotherapy DE (Dose F) | Part 2: AMG 160 + Pembrolizumab 0.03 mg SDPC1 | Part 2: AMG 160 + Pembrolizumab 0.3 mg SDPC2 | Part 2: AMG 160 + Pembrolizumab 0.15 mg eIVPC3-3d-Inf | Part 2: AMG 160 + Pembrolizumab 0.3 mg eIVPC4-3d-Inf | Part 2: AMG 160 + Pembrolizumab 0.15 mg eIVPC3-3d-Inf D-RP2D | Part 3: AMG 160 With CRS Prophylaxis 0.9 mg SDEC1 | Part 3: AMG 160 With CRS Prophylaxis 0.3 mg eIVEC1-3d-Inf | Part 4: AMG 160 Monotherapy 0.3 mg 24HR | Part 5: AMG 160 Monotherapy 0.3 mg 8HR |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Time to Symptomatic Skeletal Events (SSE)- Parts 1, 2, 3, 4, and 5 | NA (NA to NA) | NA (0.56 to NA) | NA (NA to NA) | NA (NA to NA) | NA (1.87 to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | 4.90 (NA to NA) | NA (1.15 to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (17.58 to NA) | NA (NA to NA) |
Serum concentrations of AMG 160 were determined using a validated assay. Noncompartmental analysis was performed for the estimation of pharmacokinetic (PK) parameters. Concentrations below the lower limit of quantification (LLOQ) (0.0500 ng/mL) were set to zero before data analysis. PK parameters, including Cmax, Tmax, Cmin, AUClast, AUCtau, t1/2,z, were not estimated for Parts 4 and 5 because the PK sampling schedule in these parts was sparse and not designed to support parameter estimation.
| ng/mL | Part 1A: AMG 160 Monotherapy 0.003 mg | Part 1A: AMG 160 Monotherapy 0.01 mg | Part 1A: AMG 160 Monotherapy 0.03 mg | Part 1A: AMG 160 Monotherapy 0.03 mg SD1 | Part 1A: AMG 160 Monotherapy 0.09 mg SD2 | Part 1A: AMG 160 Monotherapy 0.3 mg SD3 | Part 1A: AMG 160 Monotherapy 0.9 mg SD4 | Part 1A: AMG 160 Monotherapy 0.9 mg SD5 | Part 1A: AMG 160 0.9 mg + Tocilizumab SD6 | Part 1A: AMG 160 Monotherapy 0.9 mg SD7 | Part 1B1: AMG 160 Monotherapy 0.09 mg eIV1-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.3 mg eIV2-2d-Inf | Part 1B1: AMG 160 Monotherapy 0.3 mg eIV2-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.9 mg eIV3-2d-Inf | Part 1B1: AMG 160 Monotherapy 0.9 mg eIV3-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.6 mg eIV4-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.3 mg eIV5-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.3 mg eIV5-5d-Inf | Part 1B2: AMG 160 Monotherapy 0.09 mg eIVJC1-3d-Inf | Part 1B2: AMG 160 Monotherapy 0.3 mg eIVJC2-3d-Inf | Part 1: AMG Monotherapy DE (Dose F) | Part 2: AMG 160 + Pembrolizumab 0.03 mg SDPC1 | Part 2: AMG 160 + Pembrolizumab 0.3 mg SDPC2 | Part 2: AMG 160 + Pembrolizumab 0.15 mg eIVPC3-3d-Inf | Part 2: AMG 160 + Pembrolizumab 0.3 mg eIVPC4-3d-Inf | Part 2: AMG 160 + Pembrolizumab 0.15 mg eIVPC3-3d-Inf D-RP2D | Part 3: AMG 160 With CRS Prophylaxis 0.9 mg SDEC1 | Part 3: AMG 160 With CRS Prophylaxis 0.3 mg eIVEC1-3d-Inf |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cycle 1 day 1 | 1.07 (0.561 to 1.41) | 5.26 (2.07 to 6.70) | 10.4 (10.4 to 10.4) | 2.95 (2.88 to 10.5) | 3.20 (1.67 to 4.64) | 2.07 (1.63 to 16.3) | 6.17 (5.21 to 10.1) | 7.09 (5.75 to 9.56) | 5.96 (3.40 to 14.9) | 8.56 (5.96 to 17.0) | 4.71 (3.27 to 6.15) | 8.40 (7.14 to 9.66) | 7.41 (5.64 to 9.17) | 11.6 (10.7 to 12.5) | 26.0 (26.0 to 26.0) | 10.7 (10.3 to 15.4) | 12.1 (9.57 to 14.2) | 10.3 (5.02 to 14.8) | 13.4 (9.39 to 20.3) | 15.4 (9.12 to 31.7) | 11.1 (3.73 to 75.0) | 3.68 (2.04 to 4.50) | 2.01 (1.85 to 2.13) | 12.4 (8.14 to 19.7) | 11.8 (7.76 to 14.8) | 12.5 (10.6 to 14.4) | 13.2 (5.76 to 15.5) | 16.2 (8.12 to 25.3) |
| Cycle 1 day 8 | — | — | — | 7.82 (6.98 to 9.78) | 17.7 (13.4 to 24.4) | 22.6 (18.9 to 41.1) | 21.0 (17.7 to 26.2) | 19.6 (13.8 to 25.2) | 21.0 (12.0 to 34.7) | 10.5 (10.1 to 12.7) | 24.4 (17.7 to 26.4) | 53.1 (53.1 to 53.1) | 64.8 (64.4 to 65.1) | 187 (150 to 223) | 172 (172 to 172) | 93.5 (88.8 to 99.6) | 66.9 (63.1 to 98.3) | 73.1 (43.9 to 92.4) | 25.1 (20.2 to 25.3) | 88.4 (71.5 to 119) | 66.6 (30.7 to 566) | 7.18 (5.14 to 11.0) | 16.0 (14.2 to 17.9) | 31.3 (27.1 to 43.1) | 65.0 (57.3 to 86.7) | — | 16.2 (15.9 to 16.4) | 62.3 (54.8 to 86.8) |
| Cycle 1 day 15 | 0.812 (0.406 to 1.56) | 3.56 (1.85 to 6.30) | — | — | — | 67.8 (0.932 to 91.2) | 191 (166 to 262) | 191 (141 to 194) | 209 (164 to 249) | 21.7 (18.0 to 25.2) | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 153 (123 to 183) | — |
| Cycle 1 day 22 | — | — | — | 6.90 (6.06 to 7.60) | 19.9 (16.7 to 23.0) | — | — | — | — | 161 (50.9 to 236) | 16.6 (3.22 to 22.1) | 47.1 (41.2 to 53.0) | — | — | 200 (200 to 200) | 113 (109 to 123) | 61.6 (13.1 to 85.2) | 67.7 (64.3 to 112) | 24.1 (3.02 to 40.6) | 92.3 (57.0 to 116) | 64.8 (10.8 to 492) | 7.50 (4.42 to 28.2) | 60.9 (53.4 to 61.2) | 21.3 (16.4 to 50.9) | 73.4 (73.4 to 73.4) | — | — | 70.6 (65.7 to 73.5) |
| Cycle 2 day 1 | 1.96 (0.925 to 3.00) | 2.97 (2.21 to 5.72) | — | 19.2 (6.86 to 31.5) | 19.1 (15.5 to 20.4) | 64.7 (4.20 to 77.7) | 188 (188 to 188) | — | 251 (251 to 251) | 155 (49.0 to 214) | 17.5 (0.297 to 27.2) | 47.3 (45.0 to 51.6) | 59.6 (58.9 to 60.2) | — | — | 95.4 (90.8 to 100) | 81.7 (68.1 to 82.6) | 63.3 (55.4 to 69.3) | 24.5 (0.621 to 49.0) | 72.2 (33.8 to 92.3) | 64.1 (3.80 to 109) | 5.99 (4.63 to 14.7) | 58.5 (56.6 to 61.9) | 31.7 (23.2 to 42.8) | 65.3 (64.3 to 66.3) | 46.7 (46.7 to 46.7) | 162 (140 to 184) | 59.0 (48.2 to 73.5) |
| Cycle 2 day 15 | 1.74 (1.12 to 2.35) | 3.67 (2.39 to 11.7) | — | 7.71 (6.38 to 9.04) | 17.3 (7.13 to 18.9) | 47.0 (7.55 to 64.4) | 155 (155 to 155) | 178 (9.25 to 207) | — | 171 (171 to 196) | 20.6 (16.6 to 23.8) | 48.6 (37.5 to 50.1) | 51.3 (46.6 to 56.0) | — | — | 104 (104 to 104) | 48.7 (48.7 to 48.7) | 62.6 (0.00 to 89.1) | 23.0 (0.255 to 23.7) | 68.0 (60.7 to 99.7) | 60.9 (1.72 to 111) | 6.24 (4.31 to 9.42) | 51.4 (42.2 to 60.6) | 31.6 (27.0 to 50.1) | — | 43.4 (43.4 to 43.4) | 142 (142 to 142) | 61.1 (51.7 to 70.5) |
Serum concentrations of AMG 160 were determined using a validated assay. Noncompartmental analysis was performed for the estimation of PK parameters. Concentrations below the LLOQ (0.0500 ng/mL) were set to zero before data analysis. Actual time post dose was used for calculations. PK parameters, including Cmax, Tmax, Cmin, AUClast, AUCtau, t1/2,z, were not estimated for Parts 4 and 5 because the PK sampling schedule in these parts was sparse and not designed to support parameter estimation.
| hours | Part 1A: AMG 160 Monotherapy 0.003 mg | Part 1A: AMG 160 Monotherapy 0.01 mg | Part 1A: AMG 160 Monotherapy 0.03 mg | Part 1A: AMG 160 Monotherapy 0.03 mg SD1 | Part 1A: AMG 160 Monotherapy 0.09 mg SD2 | Part 1A: AMG 160 Monotherapy 0.3 mg SD3 | Part 1A: AMG 160 Monotherapy 0.9 mg SD4 | Part 1A: AMG 160 Monotherapy 0.9 mg SD5 | Part 1A: AMG 160 0.9 mg + Tocilizumab SD6 | Part 1A: AMG 160 Monotherapy 0.9 mg SD7 | Part 1B1: AMG 160 Monotherapy 0.09 mg eIV1-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.3 mg eIV2-2d-Inf | Part 1B1: AMG 160 Monotherapy 0.3 mg eIV2-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.9 mg eIV3-2d-Inf | Part 1B1: AMG 160 Monotherapy 0.9 mg eIV3-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.6 mg eIV4-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.3 mg eIV5-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.3 mg eIV5-5d-Inf | Part 1B2: AMG 160 Monotherapy 0.09 mg eIVJC1-3d-Inf | Part 1B2: AMG 160 Monotherapy 0.3 mg eIVJC2-3d-Inf | Part 1: AMG Monotherapy DE (Dose F) | Part 2: AMG 160 + Pembrolizumab 0.03 mg SDPC1 | Part 2: AMG 160 + Pembrolizumab 0.3 mg SDPC2 | Part 2: AMG 160 + Pembrolizumab 0.15 mg eIVPC3-3d-Inf | Part 2: AMG 160 + Pembrolizumab 0.3 mg eIVPC4-3d-Inf | Part 2: AMG 160 + Pembrolizumab 0.15 mg eIVPC3-3d-Inf D-RP2D | Part 3: AMG 160 With CRS Prophylaxis 0.9 mg SDEC1 | Part 3: AMG 160 With CRS Prophylaxis 0.3 mg eIVEC1-3d-Inf |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cycle 1 day 1 | 1.8 (1.4 to 1.9) | 1.6 (1.1 to 1.7) | 1.9 (1.9 to 1.9) | 1.6 (1.1 to 2.1) | 1.8 (1.1 to 3.4) | 1.5 (1.2 to 3.6) | 1.7 (1.1 to 2.1) | 1.8 (1.6 to 4.5) | 1.4 (1.3 to 7.6) | 1.7 (1.5 to 170) | 61 (49 to 72) | 60 (48 to 72) | 72 (72 to 72) | 49 (48 to 49) | 73 (73 to 73) | 61 (48 to 74) | 72 (72 to 73) | 84 (48 to 170) | 72 (24 to 72) | 72 (24 to 72) | 72 (2.0 to 170) | 1.6 (1.3 to 1.7) | 1.7 (1.2 to 1.9) | 72 (48 to 72) | 72 (48 to 74) | 72 (72 to 72) | 7.5 (1.5 to 7.7) | 73 (69 to 170) |
| Cycle 1 day 8 | — | — | — | 1.6 (1.6 to 3.0) | 2.7 (1.6 to 3.8) | 1.6 (1.2 to 1.8) | 1.5 (1.3 to 1.8) | 1.6 (1.4 to 1.7) | 1.3 (1.0 to 1.6) | 1.6 (0.0 to 1.9) | 1.5 (1.1 to 1.8) | 1.6 (1.2 to 1.9) | 1.7 (1.7 to 1.7) | 1.9 (1.8 to 2.1) | 7.1 (7.1 to 7.1) | 1.6 (1.1 to 1.9) | 1.2 (1.1 to 1.9) | 1.6 (1.0 to 7.4) | 1.7 (1.6 to 1.8) | 1.6 (1.5 to 1.7) | 1.5 (0.67 to 73) | 1.6 (1.5 to 2.2) | 1.6 (1.2 to 1.9) | 1.6 (1.6 to 1.7) | 1.6 (1.1 to 6.1) | — | 1.3 (1.1 to 1.6) | 1.5 (1.2 to 1.6) |
| Cycle 1 day 15 | 1.9 (1.0 to 3.1) | 1.6 (1.4 to 3.6) | — | — | — | 1.6 (1.3 to 1.7) | 1.5 (1.1 to 1.8) | 1.6 (1.5 to 1.8) | 2.1 (1.6 to 2.6) | 1.6 (1.5 to 1.8) | — | — | — | — | — | — | — | — | — | — | — | — | 1.6 (1.4 to 3.7) | — | — | — | 1.6 (1.5 to 1.6) | — |
| Cycle 1 day 22 | — | — | — | 1.6 (1.6 to 3.0) | 1.5 (1.3 to 1.7) | — | — | — | — | 1.7 (1.6 to 2.0) | 1.8 (1.1 to 7.1) | 1.5 (1.3 to 1.7) | — | — | 1.6 (1.6 to 1.6) | 1.2 (1.2 to 1.8) | 1.8 (1.6 to 48) | 1.5 (1.0 to 1.8) | 1.8 (1.7 to 1.9) | 1.8 (1.6 to 2.0) | 1.6 (0.92 to 26) | 1.6 (1.0 to 2.9) | — | 1.6 (1.6 to 7.2) | 1.7 (1.7 to 1.7) | — | — | 1.6 (1.4 to 6.6) |
| Cycle 2 day 1 | 1.6 (1.5 to 1.6) | 1.5 (1.3 to 1.7) | — | 1.5 (1.3 to 1.7) | 1.5 (1.4 to 3.1) | 1.6 (1.2 to 1.7) | 1.8 (1.8 to 1.8) | — | 1.6 (1.6 to 1.6) | 1.7 (1.5 to 1.8) | 1.6 (1.3 to 1.7) | 1.5 (1.3 to 3.6) | 2.1 (1.6 to 2.6) | — | — | 1.3 (1.3 to 1.3) | 1.5 (1.2 to 1.6) | 1.6 (1.5 to 3.7) | 1.9 (1.8 to 1.9) | 1.9 (1.8 to 3.5) | 1.6 (0.0 to 24) | 1.7 (1.5 to 340) | 1.7 (1.3 to 1.9) | 4.1 (1.5 to 8.0) | 1.5 (1.4 to 1.7) | 1.7 (1.7 to 1.7) | 1.6 (1.5 to 1.6) | 2.4 (1.5 to 3.3) |
| Cycle 2 day 15 | 2.0 (1.3 to 2.7) | 1.7 (1.5 to 3.7) | — | 2.4 (1.7 to 3.0) | 1.4 (1.1 to 1.7) | 1.6 (1.5 to 3.0) | 1.6 (1.6 to 1.6) | 1.7 (1.5 to 1.8) | — | 1.6 (1.6 to 2.0) | 1.5 (0.97 to 1.7) | 1.6 (1.2 to 1.7) | 1.7 (1.6 to 1.8) | — | — | 1.1 (1.1 to 1.1) | 1.2 (1.2 to 1.2) | 1.3 (0.0 to 2.8) | 1.8 (1.7 to 1.9) | 1.8 (1.5 to 3.7) | 1.6 (0.0 to 220) | 1.5 (1.5 to 2.1) | 1.6 (1.5 to 1.6) | 1.5 (1.4 to 6.8) | — | 1.6 (1.6 to 1.6) | 3.5 (3.5 to 3.5) | 2.1 (1.6 to 2.7) |
Serum concentrations of AMG 160 were determined using a validated assay. Noncompartmental analysis was performed for the estimation of PK parameters. Concentrations below the LLOQ (0.0500 ng/mL) were set to zero before data analysis. PK parameters, including Cmax, Tmax, Cmin, AUClast, AUCtau, t1/2,z, were not estimated for Parts 4 and 5 because the PK sampling schedule in these parts was sparse and not designed to support parameter estimation.
| ng/mL | Part 1A: AMG 160 Monotherapy 0.003 mg | Part 1A: AMG 160 Monotherapy 0.01 mg | Part 1A: AMG 160 Monotherapy 0.03 mg | Part 1A: AMG 160 Monotherapy 0.03 mg SD1 | Part 1A: AMG 160 Monotherapy 0.09 mg SD2 | Part 1A: AMG 160 Monotherapy 0.3 mg SD3 | Part 1A: AMG 160 Monotherapy 0.9 mg SD4 | Part 1A: AMG 160 Monotherapy 0.9 mg SD5 | Part 1A: AMG 160 0.9 mg + Tocilizumab SD6 | Part 1A: AMG 160 Monotherapy 0.9 mg SD7 | Part 1B1: AMG 160 Monotherapy 0.09 mg eIV1-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.3 mg eIV2-2d-Inf | Part 1B1: AMG 160 Monotherapy 0.3 mg eIV2-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.9 mg eIV3-2d-Inf | Part 1B1: AMG 160 Monotherapy 0.9 mg eIV3-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.6 mg eIV4-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.3 mg eIV5-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.3 mg eIV5-5d-Inf | Part 1B2: AMG 160 Monotherapy 0.09 mg eIVJC1-3d-Inf | Part 1B2: AMG 160 Monotherapy 0.3 mg eIVJC2-3d-Inf | Part 1: AMG Monotherapy DE (Dose F) | Part 2: AMG 160 + Pembrolizumab 0.03 mg SDPC1 | Part 2: AMG 160 + Pembrolizumab 0.3 mg SDPC2 | Part 2: AMG 160 + Pembrolizumab 0.15 mg eIVPC3-3d-Inf | Part 2: AMG 160 + Pembrolizumab 0.3 mg eIVPC4-3d-Inf | Part 2: AMG 160 + Pembrolizumab 0.15 mg eIVPC3-3d-Inf D-RP2D | Part 3: AMG 160 With CRS Prophylaxis 0.9 mg SDEC1 | Part 3: AMG 160 With CRS Prophylaxis 0.3 mg eIVEC1-3d-Inf |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cycle 1 day 1 | 0.0629 (0.00 to 0.0946) | 0.268 (0.0657 to 0.430) | 0.537 (0.537 to 0.537) | 0.452 (0.370 to 1.55) | 0.552 (0.00 to 0.784) | 0.631 (0.179 to 1.01) | 0.851 (0.168 to 1.55) | 0.900 (0.803 to 1.09) | 0.629 (0.367 to 2.48) | 6.67 (2.63 to 10.7) | 2.01 (1.24 to 2.78) | 2.90 (2.90 to 2.90) | 2.52 (2.41 to 2.62) | 4.18 (4.18 to 4.18) | 11.0 (11.0 to 11.0) | 4.13 (1.38 to 4.86) | 3.28 (2.40 to 4.46) | 9.87 (4.94 to 14.8) | 4.31 (3.76 to 4.58) | 4.89 (3.32 to 8.48) | 4.11 (0.712 to 47.8) | 0.311 (0.0765 to 0.462) | 0.331 (0.326 to 0.339) | 4.73 (4.63 to 4.84) | 3.82 (3.25 to 5.48) | 4.54 (3.44 to 5.64) | 1.70 (1.56 to 1.84) | 7.87 (5.42 to 8.12) |
| Cycle 1 day 8 | — | — | — | 0.617 (0.450 to 0.881) | 1.19 (0.790 to 1.98) | — | 2.66 (1.12 to 3.01) | 2.17 (1.52 to 3.55) | 1.92 (1.04 to 3.40) | — | 1.99 (0.435 to 2.38) | 3.88 (3.88 to 3.88) | 3.79 (3.79 to 3.79) | 8.76 (8.76 to 8.76) | 10.4 (10.4 to 10.4) | 3.74 (3.60 to 6.79) | 4.09 (1.91 to 5.61) | 5.50 (0.00 to 13.4) | 1.58 (0.181 to 2.22) | 3.46 (2.44 to 7.13) | 4.94 (0.179 to 15.4) | 0.369 (0.252 to 0.807) | 2.79 (2.24 to 3.04) | 3.68 (1.68 to 3.70) | 4.41 (4.41 to 4.41) | — | 2.76 (2.31 to 3.20) | 3.45 (2.87 to 8.47) |
| Cycle 1 day 15 | 0.100 (0.0730 to 0.127) | 0.245 (0.0923 to 0.551) | — | — | — | 2.44 (0.00 to 4.17) | 3.48 (0.00 to 6.80) | 8.16 (0.794 to 10.2) | 4.56 (4.32 to 6.18) | 2.79 (0.00 to 4.67) | — | — | — | — | — | — | — | — | — | — | — | — | 3.16 (2.01 to 4.13) | — | — | — | 6.44 (5.63 to 7.24) | — |
| Cycle 1 day 22 | — | — | — | 0.616 (0.443 to 0.789) | 1.24 (0.972 to 1.49) | — | — | — | — | 6.24 (0.00 to 14.4) | 2.04 (0.00 to 2.25) | 2.19 (0.474 to 3.90) | — | — | 11.5 (11.5 to 11.5) | 4.63 (3.71 to 5.55) | 2.34 (1.71 to 2.60) | 5.44 (2.92 to 7.96) | 1.76 (0.00 to 2.72) | 3.64 (2.83 to 4.25) | 4.62 (0.00 to 14.6) | 0.440 (0.298 to 1.07) | — | 1.84 (1.73 to 3.79) | — | — | — | 3.60 (3.35 to 3.84) |
| Cycle 2 day 1 | 0.164 (0.0916 to 0.236) | 0.235 (0.120 to 0.491) | — | 1.29 (0.483 to 2.10) | 1.25 (0.113 to 1.59) | 0.650 (0.00 to 1.30) | 5.31 (5.31 to 5.31) | — | — | 8.57 (4.43 to 11.5) | 1.81 (0.979 to 1.89) | 3.20 (0.533 to 3.67) | 2.55 (2.44 to 2.65) | — | — | 5.37 (4.92 to 5.82) | 2.72 (2.20 to 3.23) | 5.40 (2.78 to 8.02) | 1.73 (0.00 to 4.15) | 3.33 (1.79 to 3.78) | 4.36 (0.00 to 81.3) | 0.278 (0.00 to 14.7) | 2.95 (1.75 to 4.14) | 2.29 (2.12 to 3.75) | 0.00 (0.00 to 0.00) | 3.18 (3.18 to 3.18) | 7.27 (7.27 to 7.27) | 3.48 (2.99 to 3.96) |
| Cycle 2 day 15 | 0.153 (0.115 to 0.191) | 0.250 (0.176 to 0.827) | — | 0.700 (0.439 to 0.960) | 1.21 (0.00 to 1.90) | 0.853 (0.00 to 2.31) | 7.51 (7.51 to 7.51) | 4.27 (0.00 to 6.87) | — | 7.19 (4.18 to 10.2) | 1.49 (0.796 to 2.27) | 4.66 (3.94 to 5.37) | 2.58 (2.16 to 3.00) | — | — | 6.40 (5.23 to 7.57) | 1.69 (1.69 to 1.69) | 3.65 (3.43 to 7.64) | 1.96 (1.41 to 2.50) | 4.15 (3.40 to 5.89) | 4.18 (0.00 to 21.6) | 0.300 (0.285 to 0.315) | 0.423 (0.423 to 0.423) | 2.90 (1.44 to 3.86) | — | 3.05 (3.05 to 3.05) | 6.83 (6.83 to 6.83) | 3.02 (3.02 to 3.02) |
Serum concentrations of AMG 160 were determined using a validated assay. Noncompartmental analysis was performed for the estimation of PK parameters. Concentrations below the LLOQ (0.0500 ng/mL) were set to zero before data analysis. PK parameters, including Cmax, Tmax, Cmin, AUClast, AUCtau, t1/2,z, were not estimated for Parts 4 and 5 because the PK sampling schedule in these parts was sparse and not designed to support parameter estimation.
| hour*ng/mL | Part 1A: AMG 160 Monotherapy 0.003 mg | Part 1A: AMG 160 Monotherapy 0.01 mg | Part 1A: AMG 160 Monotherapy 0.03 mg | Part 1A: AMG 160 Monotherapy 0.03 mg SD1 | Part 1A: AMG 160 Monotherapy 0.09 mg SD2 | Part 1A: AMG 160 Monotherapy 0.3 mg SD3 | Part 1A: AMG 160 Monotherapy 0.9 mg SD4 | Part 1A: AMG 160 Monotherapy 0.9 mg SD5 | Part 1A: AMG 160 0.9 mg + Tocilizumab SD6 | Part 1A: AMG 160 Monotherapy 0.9 mg SD7 | Part 1B1: AMG 160 Monotherapy 0.09 mg eIV1-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.3 mg eIV2-2d-Inf | Part 1B1: AMG 160 Monotherapy 0.3 mg eIV2-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.9 mg eIV3-2d-Inf | Part 1B1: AMG 160 Monotherapy 0.9 mg eIV3-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.6 mg eIV4-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.3 mg eIV5-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.3 mg eIV5-5d-Inf | Part 1B2: AMG 160 Monotherapy 0.09 mg eIVJC1-3d-Inf | Part 1B2: AMG 160 Monotherapy 0.3 mg eIVJC2-3d-Inf | Part 1: AMG Monotherapy DE (Dose F) | Part 2: AMG 160 + Pembrolizumab 0.03 mg SDPC1 | Part 2: AMG 160 + Pembrolizumab 0.3 mg SDPC2 | Part 2: AMG 160 + Pembrolizumab 0.15 mg eIVPC3-3d-Inf | Part 2: AMG 160 + Pembrolizumab 0.3 mg eIVPC4-3d-Inf | Part 2: AMG 160 + Pembrolizumab 0.15 mg eIVPC3-3d-Inf D-RP2D | Part 3: AMG 160 With CRS Prophylaxis 0.9 mg SDEC1 | Part 3: AMG 160 With CRS Prophylaxis 0.3 mg eIVEC1-3d-Inf |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cycle 1 day 1 | 84.4 (33.1 to 114) | 379 (126 to 485) | 759 (759 to 759) | 170 (166 to 625) | 200 (68.3 to 308) | 145 (77.9 to 1190) | 380 (308 to 614) | 422 (367 to 457) | 282 (177 to 940) | 505 (186 to 905) | 581 (332 to 831) | 586 (456 to 717) | 825 (607 to 1040) | 813 (498 to 1130) | 2760 (2760 to 2760) | 1160 (1040 to 2570) | 1290 (957 to 2840) | 1010 (131 to 1760) | 1050 (752 to 1970) | 1670 (1150 to 3170) | 1140 (197 to 5890) | 123 (70.1 to 211) | 123 (116 to 144) | 1090 (651 to 1330) | 998 (524 to 1330) | 1360 (1300 to 1430) | 727 (164 to 914) | 1650 (959 to 2750) |
| Cycle 1 day 8 | — | — | — | 734 (551 to 822) | 1260 (308 to 1610) | 828 (724 to 1020) | 1070 (720 to 1090) | 924 (644 to 1190) | 832 (531 to 1720) | 423 (357 to 794) | 2010 (1100 to 2430) | 3640 (3130 to 4150) | 3570 (2970 to 4160) | 11400 (11300 to 11600) | 13500 (13500 to 13500) | 6010 (4630 to 6820) | 5030 (3260 to 6340) | 5200 (529 to 7340) | 2020 (1520 to 2020) | 4940 (3680 to 7400) | 5660 (1720 to 8710) | 599 (131 to 1170) | 856 (821 to 912) | 2710 (2060 to 3560) | 4020 (3820 to 5230) | — | 1030 (1020 to 1050) | 5050 (4300 to 8190) |
| Cycle 1 day 15 | 78.0 (12.9 to 132) | 322 (131 to 658) | — | — | — | 4370 (25.1 to 6690) | 10400 (4150 to 13600) | 11600 (8850 to 16900) | 12200 (7630 to 14200) | 1060 (495 to 1620) | — | — | — | — | — | — | — | — | — | — | — | — | 4370 (3960 to 4710) | — | — | — | 12000 (10900 to 13200) | — |
| Cycle 1 day 22 | — | — | — | 497 (492 to 678) | 1610 (1090 to 1860) | — | — | — | — | 9100 (310 to 16300) | 1840 (17.0 to 2090) | 3080 (1890 to 4270) | — | — | 11200 (11200 to 11200) | 6430 (4160 to 7620) | 4310 (1840 to 4350) | 4330 (1830 to 9340) | 1960 (42.0 to 3400) | 5720 (4430 to 5980) | 5420 (84.4 to 11200) | 806 (408 to 1150) | — | 2080 (1870 to 4350) | 4360 (4360 to 4360) | — | — | 4800 (4650 to 5870) |
| Cycle 2 day 1 | 138 (92.3 to 243) | 280 (167 to 507) | — | 1440 (537 to 2340) | 1320 (645 to 1820) | 2330 (53.3 to 5710) | 9780 (9780 to 9780) | — | 11300 (11300 to 11300) | 9240 (451 to 14500) | 1600 (0.605 to 2290) | 3030 (1960 to 4730) | 3420 (3370 to 3470) | — | — | 6000 (5640 to 6350) | 3670 (2850 to 4350) | 3980 (353 to 6600) | 2020 (1.33 to 4010) | 4710 (2710 to 5570) | 5220 (18.1 to 12600) | 420 (129 to 2000) | 3190 (1970 to 4400) | 2870 (2100 to 3720) | 2440 (1260 to 3610) | 3570 (3570 to 3570) | 6570 (4540 to 8600) | 5040 (4310 to 5770) |
| Cycle 2 day 15 | 178 (126 to 230) | 306 (138 to 1030) | — | 710 (547 to 873) | 1330 (121 to 1850) | 3030 (78.3 to 3250) | 9470 (9470 to 9470) | 9430 (22.9 to 12200) | — | 9090 (7820 to 11100) | 1660 (1100 to 2220) | 4290 (1510 to 4810) | 3260 (2870 to 3640) | — | — | 7350 (6930 to 7770) | 3430 (3430 to 3430) | 5580 (5100 to 7550) | 1770 (0.223 to 2080) | 5550 (3940 to 6510) | 5190 (7.60 to 12400) | 372 (107 to 536) | 2930 (2670 to 3190) | 2560 (2050 to 3990) | — | 3490 (3490 to 3490) | 8640 (8640 to 8640) | 4090 (404 to 4130) |
Serum concentrations of AMG 160 were determined using a validated assay. Noncompartmental analysis was performed for the estimation of PK parameters. Concentrations below the LLOQ (0.0500 ng/mL) were set to zero before data analysis. PK parameters, including Cmax, Tmax, Cmin, AUClast, AUCtau, t1/2,z, were not estimated for Parts 4 and 5 because the PK sampling schedule in these parts was sparse and not designed to support parameter estimation.
| hour*ng/mL | Part 1A: AMG 160 Monotherapy 0.003 mg | Part 1A: AMG 160 Monotherapy 0.01 mg | Part 1A: AMG 160 Monotherapy 0.03 mg | Part 1A: AMG 160 Monotherapy 0.03 mg SD1 | Part 1A: AMG 160 Monotherapy 0.09 mg SD2 | Part 1A: AMG 160 Monotherapy 0.3 mg SD3 | Part 1A: AMG 160 Monotherapy 0.9 mg SD4 | Part 1A: AMG 160 Monotherapy 0.9 mg SD5 | Part 1A: AMG 160 0.9 mg + Tocilizumab SD6 | Part 1A: AMG 160 Monotherapy 0.9 mg SD7 | Part 1B1: AMG 160 Monotherapy 0.09 mg eIV1-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.3 mg eIV2-2d-Inf | Part 1B1: AMG 160 Monotherapy 0.3 mg eIV2-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.9 mg eIV3-2d-Inf | Part 1B1: AMG 160 Monotherapy 0.9 mg eIV3-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.6 mg eIV4-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.3 mg eIV5-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.3 mg eIV5-5d-Inf | Part 1B2: AMG 160 Monotherapy 0.09 mg eIVJC1-3d-Inf | Part 1B2: AMG 160 Monotherapy 0.3 mg eIVJC2-3d-Inf | Part 1: AMG Monotherapy DE (Dose F) | Part 2: AMG 160 + Pembrolizumab 0.03 mg SDPC1 | Part 2: AMG 160 + Pembrolizumab 0.3 mg SDPC2 | Part 2: AMG 160 + Pembrolizumab 0.15 mg eIVPC3-3d-Inf | Part 2: AMG 160 + Pembrolizumab 0.3 mg eIVPC4-3d-Inf | Part 2: AMG 160 + Pembrolizumab 0.15 mg eIVPC3-3d-Inf D-RP2D | Part 3: AMG 160 With CRS Prophylaxis 0.9 mg SDEC1 | Part 3: AMG 160 With CRS Prophylaxis 0.3 mg eIVEC1-3d-Inf |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cycle 1 day 1 | 84.6 (39.5 to 114) | 379 (126 to 486) | 761 (761 to 761) | 171 (167 to 627) | 200 (71.4 to 308) | 145 (79.0 to 901) | 340 (309 to 620) | 425 (348 to 458) | 285 (177 to 999) | 303 (298 to 865) | 765 (765 to 765) | 716 (716 to 716) | 786 (604 to 967) | 1130 (1130 to 1130) | 2750 (2750 to 2750) | 1690 (1690 to 1690) | 1340 (1230 to 1860) | 1510 (1260 to 1750) | 1500 (1050 to 1960) | 1510 (1060 to 3160) | 1120 (487 to 5440) | 164 (70.1 to 212) | 124 (116 to 136) | 1240 (921 to 1330) | 1090 (914 to 1260) | 1230 (1230 to 1230) | 821 (728 to 913) | 945 (945 to 945) |
| Cycle 1 day 8 | — | — | — | 735 (554 to 809) | 1320 (356 to 1800) | 1160 (964 to 1260) | 1080 (692 to 1100) | 929 (648 to 1270) | 847 (532 to 1730) | 582 (422 to 802) | 2010 (1100 to 2430) | 4030 (3920 to 4150) | 3890 (3510 to 4260) | 12700 (11600 to 13900) | 13500 (13500 to 13500) | 6140 (5220 to 6790) | 5000 (3820 to 6240) | 5480 (4040 to 7350) | 2020 (1440 to 2030) | 5420 (3680 to 7400) | 5750 (2700 to 8770) | 496 (170 to 807) | 924 (833 to 927) | 2790 (2060 to 3560) | 5280 (4820 to 5340) | — | 1030 (1020 to 1050) | 5050 (4300 to 8190) |
| Cycle 1 day 15 | 78.1 (26.5 to 133) | 319 (132 to 660) | — | — | — | 4330 (29.8 to 6700) | 9930 (4160 to 12200) | 11700 (10100 to 16900) | 10900 (7630 to 14200) | 1100 (503 to 1620) | — | — | — | — | — | — | — | — | — | — | — | — | 4110 (3970 to 4370) | — | — | — | 12000 (10900 to 13200) | — |
| Cycle 1 day 22 | — | — | — | 484 (384 to 488) | 1230 (822 to 1460) | — | — | — | — | 7440 (310 to 12000) | 1270 (49.7 to 1580) | 2430 (1670 to 3200) | — | — | 8930 (8930 to 8930) | 4840 (4140 to 6340) | 3380 (1320 to 3750) | 3470 (2900 to 6250) | 1590 (46.5 to 2540) | 4460 (3440 to 5960) | 4320 (97.3 to 7390) | 595 (286 to 965) | — | 1660 (1290 to 3210) | 4390 (4390 to 4390) | — | — | 3980 (3890 to 5860) |
| Cycle 2 day 1 | 168 (92.6 to 243) | 282 (168 to 508) | — | 1440 (539 to 2340) | 1320 (645 to 1820) | 3010 (58.4 to 5190) | 9660 (9660 to 9660) | — | 12100 (12100 to 12100) | 9240 (475 to 14500) | 1870 (920 to 2290) | 3040 (1960 to 4650) | 3410 (3360 to 3470) | — | — | 6010 (5660 to 6370) | 3670 (3250 to 4350) | 5380 (3980 to 6780) | 3070 (2020 to 4110) | 4700 (2710 to 5490) | 5260 (19.1 to 12600) | 420 (247 to 1990) | 3200 (3090 to 4420) | 2790 (2140 to 3730) | 3640 (3040 to 4240) | 3650 (3650 to 3650) | 8030 (7460 to 8600) | 5040 (4320 to 5770) |
| Cycle 2 day 15 | 178 (126 to 230) | 304 (170 to 1030) | — | 710 (548 to 872) | 1320 (124 to 1890) | 3030 (88.4 to 3260) | 9660 (9660 to 9660) | 9580 (35.6 to 11100) | — | 11100 (7820 to 11100) | 1640 (1380 to 2310) | 4360 (1640 to 4920) | 3290 (2870 to 3720) | — | — | 7280 (6790 to 7770) | 3430 (3430 to 3430) | 5580 (5020 to 7530) | 1950 (1770 to 2130) | 5380 (4590 to 6510) | 5250 (8.53 to 12000) | 372 (123 to 536) | 3220 (2640 to 3790) | 2540 (2450 to 3990) | — | 3490 (3490 to 3490) | 8800 (8800 to 8800) | 4430 (4130 to 4730) |
Serum concentrations of AMG 160 were determined using a validated assay. Noncompartmental analysis was performed for the estimation of PK parameters. Concentrations below the LLOQ (0.0500 ng/mL) were set to zero before data analysis. PK parameters, including Cmax, Tmax, Cmin, AUClast, AUCtau, t1/2,z, were not estimated for Parts 4 and 5 because the PK sampling schedule in these parts was sparse and not designed to support parameter estimation.
| hours | Part 1A: AMG 160 Monotherapy 0.003 mg | Part 1A: AMG 160 Monotherapy 0.01 mg | Part 1A: AMG 160 Monotherapy 0.03 mg | Part 1A: AMG 160 Monotherapy 0.03 mg SD1 | Part 1A: AMG 160 Monotherapy 0.09 mg SD2 | Part 1A: AMG 160 Monotherapy 0.3 mg SD3 | Part 1A: AMG 160 Monotherapy 0.9 mg SD4 | Part 1A: AMG 160 Monotherapy 0.9 mg SD5 | Part 1A: AMG 160 0.9 mg + Tocilizumab SD6 | Part 1A: AMG 160 Monotherapy 0.9 mg SD7 | Part 1B1: AMG 160 Monotherapy 0.09 mg eIV1-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.3 mg eIV2-2d-Inf | Part 1B1: AMG 160 Monotherapy 0.3 mg eIV2-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.9 mg eIV3-2d-Inf | Part 1B1: AMG 160 Monotherapy 0.9 mg eIV3-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.6 mg eIV4-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.3 mg eIV5-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.3 mg eIV5-5d-Inf | Part 1B2: AMG 160 Monotherapy 0.09 mg eIVJC1-3d-Inf | Part 1B2: AMG 160 Monotherapy 0.3 mg eIVJC2-3d-Inf | Part 1: AMG Monotherapy DE (Dose F) | Part 2: AMG 160 + Pembrolizumab 0.03 mg SDPC1 | Part 2: AMG 160 + Pembrolizumab 0.3 mg SDPC2 | Part 2: AMG 160 + Pembrolizumab 0.15 mg eIVPC3-3d-Inf | Part 2: AMG 160 + Pembrolizumab 0.3 mg eIVPC4-3d-Inf | Part 2: AMG 160 + Pembrolizumab 0.15 mg eIVPC3-3d-Inf D-RP2D | Part 3: AMG 160 With CRS Prophylaxis 0.9 mg SDEC1 | Part 3: AMG 160 With CRS Prophylaxis 0.3 mg eIVEC1-3d-Inf |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cycle 1 day 1 | 98.1 (68.3 to 121) | 98.7 (88.9 to 128) | 108 (108 to 108) | 74.7 (74.7 to 74.7) | 21.5 (21.5 to 21.5) | 85.2 (65.1 to 105) | 66.1 (59.3 to 72.9) | 61.7 (52.2 to 71.1) | 68.5 (59.6 to 77.5) | — | — | — | — | — | — | — | — | — | — | — | — | 71.4 (47.1 to 76.3) | — | — | — | — | 62.3 (62.3 to 62.3) | — |
| Cycle 1 day 8 | — | — | — | 120 (117 to 123) | 124 (27.9 to 129) | 27.3 (27.3 to 27.3) | 76.1 (74.7 to 77.6) | 52.5 (52.5 to 52.5) | 72.1 (69.8 to 74.4) | 29.3 (29.3 to 29.3) | 113 (71.8 to 127) | 137 (137 to 137) | 102 (81.2 to 123) | 115 (115 to 115) | 124 (124 to 124) | 114 (106 to 130) | 96.3 (70.6 to 132) | 109 (105 to 114) | 95.3 (50.9 to 140) | 88.0 (83.0 to 113) | 105 (40.1 to 146) | 109 (92.6 to 136) | — | 115 (106 to 123) | 118 (118 to 118) | — | 75.9 (75.9 to 75.9) | 91.3 (90.8 to 124) |
| Cycle 1 day 15 | 131 (129 to 133) | 113 (108 to 128) | — | — | — | 96.4 (22.9 to 111) | 113 (14.3 to 136) | 74.2 (44.8 to 129) | 98.5 (79.5 to 152) | 11.3 (11.3 to 11.3) | — | — | — | — | — | — | — | — | — | — | — | — | 138 (118 to 152) | — | — | — | 93.6 (93.6 to 93.6) | — |
| Cycle 1 day 22 | — | — | — | 127 (127 to 127) | 112 (86.8 to 126) | — | — | — | — | 104 (80.6 to 126) | 127 (120 to 150) | 105 (70.7 to 139) | — | — | 94.5 (94.5 to 94.5) | 94.8 (48.3 to 132) | 89.7 (68.6 to 96.3) | 117 (93.6 to 141) | 99.0 (13.3 to 106) | 96.3 (68.0 to 112) | 112 (68.0 to 142) | 103 (84.8 to 159) | — | 135 (134 to 136) | 71.6 (71.6 to 71.6) | — | — | 83.1 (68.2 to 91.5) |
| Cycle 2 day 1 | 131 (127 to 136) | 113 (106 to 118) | — | 127 (125 to 130) | 108 (62.5 to 142) | 70.2 (22.1 to 115) | 117 (117 to 117) | — | 69.3 (69.3 to 69.3) | 100 (59.3 to 126) | 116 (104 to 116) | 119 (72.9 to 157) | 118 (101 to 134) | — | — | 131 (122 to 139) | 74.5 (62.3 to 97.5) | 109 (95.8 to 122) | 115 (106 to 123) | 109 (82.5 to 144) | 102 (5.20 to 146) | 104 (47.8 to 111) | 102 (86.0 to 117) | 106 (95.2 to 133) | 70.0 (70.0 to 70.0) | 108 (108 to 108) | 107 (107 to 107) | 99.1 (93.9 to 104) |
| Cycle 2 day 15 | 111 (110 to 113) | 105 (101 to 117) | — | 125 (108 to 141) | 114 (40.1 to 129) | 68.1 (9.53 to 123) | 113 (113 to 113) | 118 (102 to 134) | — | 129 (114 to 144) | 108 (92.1 to 111) | 110 (55.7 to 120) | 105 (97.6 to 113) | — | — | 125 (116 to 134) | 85.6 (85.6 to 85.6) | 100 (98.4 to 104) | 124 (111 to 138) | 101 (68.6 to 148) | 101 (5.73 to 135) | 98.1 (24.4 to 120) | 66.8 (66.8 to 66.8) | 109 (72.3 to 135) | — | 104 (104 to 104) | 90.8 (90.8 to 90.8) | 87.9 (69.8 to 106) |
A treatment-emergent adverse event is one that occurs on or after the first dose of study treatment and up to 30 days after the last dose. Adverse events were graded using Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Any clinically significant changes in vital signs, electrocardiograms, and clinical laboratory tests were recorded as adverse events.
| Participants | Part 1A: AMG 160 Monotherapy 0.003 mg | Part 1A: AMG 160 Monotherapy 0.01 mg | Part 1A: AMG 160 Monotherapy 0.03 mg | Part 1A: AMG 160 Monotherapy 0.03 mg SD1 | Part 1A: AMG 160 Monotherapy 0.09 mg SD2 | Part 1A: AMG 160 Monotherapy 0.3 mg SD3 | Part 1A: AMG 160 Monotherapy 0.9 mg SD4 | Part 1A: AMG 160 Monotherapy 0.9 mg SD5 | Part 1A: AMG 160 0.9 mg + Tocilizumab SD6 | Part 1A: AMG 160 Monotherapy 0.9 mg SD7 | Part 1B1: AMG 160 Monotherapy 0.09 mg eIV1-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.3 mg eIV2-2d-Inf | Part 1B1: AMG 160 Monotherapy 0.3 mg eIV2-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.9 mg eIV3-2d-Inf | Part 1B1: AMG 160 Monotherapy 0.9 mg eIV3-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.6 mg eIV4-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.3 mg eIV5-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.3 mg eIV5-5d-Inf | Part 1B2: AMG 160 Monotherapy 0.09 mg eIVJC1-3d-Inf | Part 1B2: AMG 160 Monotherapy 0.3 mg eIVJC2-3d-Inf | Part 1: AMG Monotherapy DE (Dose F) | Part 2: AMG 160 + Pembrolizumab 0.03 mg SDPC1 | Part 2: AMG 160 + Pembrolizumab 0.3 mg SDPC2 | Part 2: AMG 160 + Pembrolizumab 0.15 mg eIVPC3-3d-Inf | Part 2: AMG 160 + Pembrolizumab 0.3 mg eIVPC4-3d-Inf | Part 2: AMG 160 + Pembrolizumab 0.15 mg eIVPC3-3d-Inf D-RP2D | Part 3: AMG 160 With CRS Prophylaxis 0.9 mg SDEC1 | Part 3: AMG 160 With CRS Prophylaxis 0.3 mg eIVEC1-3d-Inf | Part 4: AMG 160 Monotherapy 0.3 mg 24HR | Part 5: AMG 160 Monotherapy 0.3 mg 8HR |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Treatment-emergent Adverse Events | 2 | 4 | 1 | 3 | 6 | 4 | 4 | 4 | 3 | 4 | 6 | 4 | 3 | 2 | 1 | 4 | 4 | 6 | 4 | 7 | 56 | 6 | 3 | 5 | 7 | 3 | 3 | 3 | 26 | 23 |
| Treatment (AMG 160) Related Treatment-emergent Adverse Events | 2 | 4 | 1 | 3 | 6 | 4 | 4 | 4 | 3 | 4 | 6 | 4 | 3 | 2 | 1 | 4 | 4 | 6 | 4 | 7 | 56 | 6 | 3 | 5 | 7 | 3 | 3 | 3 | 26 | 23 |
| Treatment (Pembrolizumab) Related Treatment-emergent Adverse Events | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 5 | 3 | 4 | 4 | 1 | — | — | — | — |
| Treatment (Etanercept) Related Treatment-emergent Adverse Events | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 0 | 1 | — | — |
Collected over Death: From enrollment through end of study; median (min, max) time on study was 10.5 (0.1, 37.9) months. TEAE: From 1st dose of investigational product (IP) (AMG 160 or Pembrolizumab) date to min(last dose of IP date + 30 days, EOS date , start of new anti-cancer therapy date); median (min, max) duration was 3 (0, 23.5) months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1A: AMG 160 Monotherapy 0.003 mg | 3/3 (100%) | 1/3 (33.3%) | 2/3 (66.7%) |
| Part 1A: AMG 160 Monotherapy 0.01 mg | 4/4 (100%) | 3/4 (75%) | 4/4 (100%) |
| Part 1A: AMG 160 Monotherapy 0.03 mg | 0/1 (0%) | 1/1 (100%) | 1/1 (100%) |
| Part 1A: AMG 160 Monotherapy 0.03 mg SD1 | 3/3 (100%) | 3/3 (100%) | 3/3 (100%) |
| Part 1A: AMG 160 Monotherapy 0.09 mg SD2 | 4/6 (66.7%) | 5/6 (83.3%) | 6/6 (100%) |
| Part 1A: AMG 160 Monotherapy 0.3 mg SD3 | 2/4 (50%) | 4/4 (100%) | 4/4 (100%) |
| Part 1A: AMG 160 Monotherapy 0.9 mg SD4 | 4/4 (100%) | 2/4 (50%) | 4/4 (100%) |
| Part 1A: AMG 160 Monotherapy 0.9 mg SD5 | 3/4 (75%) | 4/4 (100%) | 4/4 (100%) |
| Part 1A: AMG 160 0.9 mg + Tocilizumab SD6 | 3/3 (100%) | 3/3 (100%) | 3/3 (100%) |
| Part 1A: AMG 160 Monotherapy 0.9 mg SD7 | 4/4 (100%) | 4/4 (100%) | 4/4 (100%) |
| Part 1B1: AMG 160 Monotherapy 0.09 mg eIV1-3d-Inf | 3/6 (50%) | 2/6 (33.3%) | 6/6 (100%) |
| Part 1B1: AMG 160 Monotherapy 0.3 mg eIV2-2d-Inf | 3/4 (75%) | 2/4 (50%) | 4/4 (100%) |
| Part 1B1: AMG 160 Monotherapy 0.3 mg eIV2-3d-Inf | 2/3 (66.7%) | 1/3 (33.3%) | 3/3 (100%) |
| Part 1B1: AMG 160 Monotherapy 0.9 mg eIV3-2d-Inf | 1/2 (50%) | 0/2 (0%) | 2/2 (100%) |
| Part 1B1: AMG 160 Monotherapy 0.9 mg eIV3-3d-Inf | 1/1 (100%) | 0/1 (0%) | 1/1 (100%) |
| Part 1B1: AMG 160 Monotherapy 0.6 mg eIV4-3d-Inf | 2/4 (50%) | 2/4 (50%) | 4/4 (100%) |
| Part 1B1: AMG 160 Monotherapy 0.3 mg eIV5-3d-Inf | 3/4 (75%) | 3/4 (75%) | 4/4 (100%) |
| Part 1B1: AMG 160 Monotherapy 0.3 mg eIV5-5d-Inf | 4/6 (66.7%) | 4/6 (66.7%) | 6/6 (100%) |
| Part 1B2: AMG 160 Monotherapy 0.09 mg eIVJC1-3d-Inf | 4/4 (100%) | 1/4 (25%) | 4/4 (100%) |
| Part 1B2: AMG 160 Monotherapy 0.3 mg eIVJC2-3d-Inf | 5/7 (71.4%) | 0/7 (0%) | 7/7 (100%) |
| Part 1: AMG Monotherapy DE (Dose F) | 40/56 (71.4%) | 29/56 (51.8%) | 56/56 (100%) |
| Part 2: AMG 160 + Pembrolizumab 0.03 mg SDPC1 | 6/6 (100%) | 3/6 (50%) | 6/6 (100%) |
| Part 2: AMG 160 + Pembrolizumab 0.3 mg SDPC2 | 3/3 (100%) | 2/3 (66.7%) | 3/3 (100%) |
| Part 2: AMG 160 + Pembrolizumab Dose E eIVPC3-3d-Inf | 3/5 (60%) | 2/5 (40%) | 5/5 (100%) |
| Part 2: AMG 160 + Pembrolizumab 0.3 mg eIVPC4-3d-Inf | 4/7 (57.1%) | 6/7 (85.7%) | 7/7 (100%) |
| Part 2: AMG 160 + Pembrolizumab 0.15 mg eIVPC3-3d-Inf D-RP2D | 1/3 (33.3%) | 2/3 (66.7%) | 3/3 (100%) |
| Part 3: AMG 160 With CRS Prophylaxis 0.9 mg SDEC1 | 1/3 (33.3%) | 1/3 (33.3%) | 3/3 (100%) |
| Part 3: AMG 160 With CRS Prophylaxis 0.3 mg eIVEC1-3d-Inf | 2/3 (66.7%) | 0/3 (0%) | 3/3 (100%) |
| Part 4: AMG 160 Monotherapy 0.3 mg 24HR | 11/26 (42.3%) | 12/26 (46.2%) | 26/26 (100%) |
| Part 5: AMG 160 Monotherapy 0.3 mg 8HR | 11/23 (47.8%) | 15/23 (65.2%) | 23/23 (100%) |
| Event | Part 1A: AMG 160 Monotherapy 0.003 mg | Part 1A: AMG 160 Monotherapy 0.01 mg | Part 1A: AMG 160 Monotherapy 0.03 mg | Part 1A: AMG 160 Monotherapy 0.03 mg SD1 | Part 1A: AMG 160 Monotherapy 0.09 mg SD2 | Part 1A: AMG 160 Monotherapy 0.3 mg SD3 | Part 1A: AMG 160 Monotherapy 0.9 mg SD4 | Part 1A: AMG 160 Monotherapy 0.9 mg SD5 | Part 1A: AMG 160 0.9 mg + Tocilizumab SD6 | Part 1A: AMG 160 Monotherapy 0.9 mg SD7 | Part 1B1: AMG 160 Monotherapy 0.09 mg eIV1-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.3 mg eIV2-2d-Inf | Part 1B1: AMG 160 Monotherapy 0.3 mg eIV2-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.9 mg eIV3-2d-Inf | Part 1B1: AMG 160 Monotherapy 0.9 mg eIV3-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.6 mg eIV4-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.3 mg eIV5-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.3 mg eIV5-5d-Inf | Part 1B2: AMG 160 Monotherapy 0.09 mg eIVJC1-3d-Inf | Part 1B2: AMG 160 Monotherapy 0.3 mg eIVJC2-3d-Inf | Part 1: AMG Monotherapy DE (Dose F) | Part 2: AMG 160 + Pembrolizumab 0.03 mg SDPC1 | Part 2: AMG 160 + Pembrolizumab 0.3 mg SDPC2 | Part 2: AMG 160 + Pembrolizumab Dose E eIVPC3-3d-Inf | Part 2: AMG 160 + Pembrolizumab 0.3 mg eIVPC4-3d-Inf | Part 2: AMG 160 + Pembrolizumab 0.15 mg eIVPC3-3d-Inf D-RP2D | Part 3: AMG 160 With CRS Prophylaxis 0.9 mg SDEC1 | Part 3: AMG 160 With CRS Prophylaxis 0.3 mg eIVEC1-3d-Inf | Part 4: AMG 160 Monotherapy 0.3 mg 24HR | Part 5: AMG 160 Monotherapy 0.3 mg 8HR |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cytokine release syndromeImmune system disorders | 0/3 | 2/4 | 1/1 | 0/3 | 2/6 | 3/4 | 0/4 | 3/4 | 1/3 | 3/4 | 1/6 | 1/4 | 0/3 | 0/2 | 0/1 | 0/4 | 0/4 | 0/6 | 1/4 | 0/7 | 18/56 | 0/6 | 0/3 | 0/5 | 3/7 | 0/3 | 0/3 | 0/3 | 10/26 | 12/23 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/3 | 0/4 | 1/1 | 0/3 | 0/6 | 0/4 | 0/4 | 0/4 | 0/3 | 0/4 | 0/6 | 0/4 | 0/3 | 0/2 | 0/1 | 0/4 | 0/4 | 0/6 | 0/4 | 0/7 | 0/56 | 0/6 | 0/3 | 0/5 | 0/7 | 0/3 | 0/3 | 0/3 | 0/26 | 0/23 |
| Groin painMusculoskeletal and connective tissue disorders | 0/3 | 0/4 | 1/1 | 0/3 | 0/6 | 0/4 | 0/4 | 0/4 | 0/3 | 0/4 | 0/6 | 0/4 | 0/3 | 0/2 | 0/1 | 0/4 | 0/4 | 0/6 | 0/4 | 0/7 | 0/56 | 0/6 | 0/3 | 0/5 | 0/7 | 0/3 | 0/3 | 0/3 | 0/26 | 0/23 |
| RashSkin and subcutaneous tissue disorders | 0/3 | 0/4 | 1/1 | 0/3 | 0/6 | 0/4 | 0/4 | 0/4 | 0/3 | 0/4 | 0/6 | 0/4 | 0/3 | 0/2 | 0/1 | 0/4 | 0/4 | 0/6 | 0/4 | 0/7 | 0/56 | 0/6 | 0/3 | 0/5 | 0/7 | 0/3 | 0/3 | 0/3 | 0/26 | 0/23 |
| Back painMusculoskeletal and connective tissue disorders | 0/3 | 0/4 | 0/1 | 2/3 | 0/6 | 0/4 | 0/4 | 0/4 | 0/3 | 0/4 | 0/6 | 0/4 | 0/3 | 0/2 | 0/1 | 0/4 | 0/4 | 0/6 | 0/4 | 0/7 | 1/56 | 0/6 | 0/3 | 0/5 | 0/7 | 0/3 | 0/3 | 0/3 | 0/26 | 0/23 |
| AnaemiaBlood and lymphatic system disorders | 0/3 | 0/4 | 0/1 | 1/3 | 0/6 | 0/4 | 0/4 | 0/4 | 0/3 | 0/4 | 0/6 | 0/4 | 0/3 | 0/2 | 0/1 | 0/4 | 0/4 | 1/6 | 0/4 | 0/7 | 2/56 | 0/6 | 0/3 | 0/5 | 0/7 | 0/3 | 0/3 | 0/3 | 0/26 | 1/23 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/3 | 0/4 | 0/1 | 0/3 | 0/6 | 0/4 | 0/4 | 0/4 | 0/3 | 0/4 | 0/6 | 0/4 | 0/3 | 0/2 | 0/1 | 0/4 | 0/4 | 0/6 | 0/4 | 0/7 | 0/56 | 0/6 | 0/3 | 0/5 | 0/7 | 0/3 | 1/3 | 0/3 | 0/26 | 0/23 |
| Atrial fibrillationCardiac disorders | 0/3 | 0/4 | 0/1 | 0/3 | 1/6 | 1/4 | 1/4 | 0/4 | 0/3 | 1/4 | 0/6 | 0/4 | 0/3 | 0/2 | 0/1 | 0/4 | 1/4 | 0/6 | 0/4 | 0/7 | 1/56 | 2/6 | 0/3 | 0/5 | 0/7 | 0/3 | 1/3 | 0/3 | 0/26 | 0/23 |
| Cardiac arrestCardiac disorders | 0/3 | 0/4 | 0/1 | 0/3 | 0/6 | 0/4 | 0/4 | 0/4 | 0/3 | 0/4 | 0/6 | 0/4 | 0/3 | 0/2 | 0/1 | 0/4 | 0/4 | 0/6 | 0/4 | 0/7 | 0/56 | 0/6 | 0/3 | 0/5 | 0/7 | 1/3 | 0/3 | 0/3 | 0/26 | 0/23 |
| HypoacusisEar and labyrinth disorders | 0/3 | 0/4 | 0/1 | 0/3 | 0/6 | 0/4 | 0/4 | 0/4 | 1/3 | 0/4 | 0/6 | 0/4 | 0/3 | 0/2 | 0/1 | 0/4 | 0/4 | 0/6 | 0/4 | 0/7 | 0/56 | 0/6 | 0/3 | 0/5 | 0/7 | 0/3 | 0/3 | 0/3 | 0/26 | 0/23 |
| Event | Part 1A: AMG 160 Monotherapy 0.003 mg | Part 1A: AMG 160 Monotherapy 0.01 mg | Part 1A: AMG 160 Monotherapy 0.03 mg | Part 1A: AMG 160 Monotherapy 0.03 mg SD1 | Part 1A: AMG 160 Monotherapy 0.09 mg SD2 | Part 1A: AMG 160 Monotherapy 0.3 mg SD3 | Part 1A: AMG 160 Monotherapy 0.9 mg SD4 | Part 1A: AMG 160 Monotherapy 0.9 mg SD5 | Part 1A: AMG 160 0.9 mg + Tocilizumab SD6 | Part 1A: AMG 160 Monotherapy 0.9 mg SD7 | Part 1B1: AMG 160 Monotherapy 0.09 mg eIV1-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.3 mg eIV2-2d-Inf | Part 1B1: AMG 160 Monotherapy 0.3 mg eIV2-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.9 mg eIV3-2d-Inf | Part 1B1: AMG 160 Monotherapy 0.9 mg eIV3-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.6 mg eIV4-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.3 mg eIV5-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.3 mg eIV5-5d-Inf | Part 1B2: AMG 160 Monotherapy 0.09 mg eIVJC1-3d-Inf | Part 1B2: AMG 160 Monotherapy 0.3 mg eIVJC2-3d-Inf | Part 1: AMG Monotherapy DE (Dose F) | Part 2: AMG 160 + Pembrolizumab 0.03 mg SDPC1 | Part 2: AMG 160 + Pembrolizumab 0.3 mg SDPC2 | Part 2: AMG 160 + Pembrolizumab Dose E eIVPC3-3d-Inf | Part 2: AMG 160 + Pembrolizumab 0.3 mg eIVPC4-3d-Inf | Part 2: AMG 160 + Pembrolizumab 0.15 mg eIVPC3-3d-Inf D-RP2D | Part 3: AMG 160 With CRS Prophylaxis 0.9 mg SDEC1 | Part 3: AMG 160 With CRS Prophylaxis 0.3 mg eIVEC1-3d-Inf | Part 4: AMG 160 Monotherapy 0.3 mg 24HR | Part 5: AMG 160 Monotherapy 0.3 mg 8HR |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LymphopeniaBlood and lymphatic system disorders | 0/3 | 0/4 | 1/1 | 0/3 | 0/6 | 0/4 | 0/4 | 2/4 | 0/3 | 1/4 | 0/6 | 1/4 | 0/3 | 0/2 | 0/1 | 0/4 | 0/4 | 0/6 | 0/4 | 0/7 | 2/56 | 0/6 | 0/3 | 0/5 | 0/7 | 0/3 | 0/3 | 0/3 | 0/26 | 0/23 |
| HypoacusisEar and labyrinth disorders | 0/3 | 0/4 | 0/1 | 1/3 | 0/6 | 0/4 | 0/4 | 0/4 | 0/3 | 0/4 | 0/6 | 0/4 | 0/3 | 2/2 | 1/1 | 0/4 | 0/4 | 0/6 | 0/4 | 1/7 | 9/56 | 0/6 | 2/3 | 0/5 | 1/7 | 0/3 | 0/3 | 1/3 | 1/26 | 1/23 |
| TinnitusEar and labyrinth disorders | 0/3 | 0/4 | 0/1 | 0/3 | 0/6 | 0/4 | 1/4 | 0/4 | 0/3 | 0/4 | 1/6 | 0/4 | 1/3 | 1/2 | 1/1 | 1/4 | 0/4 | 2/6 | 0/4 | 0/7 | 1/56 | 0/6 | 1/3 | 0/5 | 0/7 | 0/3 | 0/3 | 0/3 | 2/26 | 1/23 |
| VertigoEar and labyrinth disorders | 0/3 | 0/4 | 0/1 | 1/3 | 0/6 | 0/4 | 0/4 | 0/4 | 0/3 | 0/4 | 0/6 | 0/4 | 0/3 | 0/2 | 1/1 | 0/4 | 0/4 | 0/6 | 0/4 | 0/7 | 0/56 | 0/6 | 1/3 | 1/5 | 0/7 | 0/3 | 0/3 | 0/3 | 1/26 | 0/23 |
| Abdominal distensionGastrointestinal disorders | 1/3 | 0/4 | 1/1 | 0/3 | 0/6 | 0/4 | 0/4 | 0/4 | 0/3 | 0/4 | 0/6 | 0/4 | 0/3 | 0/2 | 0/1 | 0/4 | 0/4 | 0/6 | 0/4 | 0/7 | 1/56 | 0/6 | 0/3 | 0/5 | 0/7 | 1/3 | 0/3 | 0/3 | 1/26 | 0/23 |
| DiarrhoeaGastrointestinal disorders | 0/3 | 1/4 | 0/1 | 2/3 | 3/6 | 1/4 | 2/4 | 0/4 | 1/3 | 2/4 | 6/6 | 2/4 | 3/3 | 1/2 | 1/1 | 2/4 | 2/4 | 3/6 | 1/4 | 0/7 | 30/56 | 5/6 | 2/3 | 2/5 | 2/7 | 3/3 | 3/3 | 1/3 | 14/26 | 6/23 |
| Dry mouthGastrointestinal disorders | 0/3 | 0/4 | 0/1 | 1/3 | 3/6 | 2/4 | 3/4 | 0/4 | 0/3 | 3/4 | 2/6 | 2/4 | 1/3 | 1/2 | 1/1 | 2/4 | 2/4 | 4/6 | 0/4 | 1/7 | 23/56 | 0/6 | 2/3 | 1/5 | 2/7 | 0/3 | 0/3 | 2/3 | 8/26 | 4/23 |
| NauseaGastrointestinal disorders | 0/3 | 1/4 | 1/1 | 1/3 | 4/6 | 1/4 | 2/4 | 2/4 | 1/3 | 2/4 | 4/6 | 2/4 | 2/3 | 2/2 | 0/1 | 0/4 | 1/4 | 1/6 | 1/4 | 2/7 | 32/56 | 6/6 | 2/3 | 3/5 | 2/7 | 2/3 | 3/3 | 3/3 | 19/26 | 11/23 |
| VomitingGastrointestinal disorders | 1/3 | 1/4 | 0/1 | 3/3 | 4/6 | 2/4 | 1/4 | 0/4 | 0/3 | 1/4 | 4/6 | 2/4 | 2/3 | 2/2 | 0/1 | 0/4 | 1/4 | 2/6 | 0/4 | 1/7 | 26/56 | 4/6 | 2/3 | 2/5 | 3/7 | 1/3 | 2/3 | 1/3 | 13/26 | 7/23 |
| FatigueGeneral disorders | 0/3 | 2/4 | 1/1 | 3/3 | 3/6 | 3/4 | 3/4 | 2/4 | 2/3 | 2/4 | 6/6 | 2/4 | 2/3 | 2/2 | 0/1 | 3/4 | 1/4 | 3/6 | 0/4 | 0/7 | 32/56 | 4/6 | 3/3 | 1/5 | 2/7 | 2/3 | 1/3 | 2/3 | 11/26 | 11/23 |
Safety analysis set: all participants who were enrolled and received at least one dose of AMG 160 or pembrolizumab.
| Age, Customized(Participants) | Part 1A: AMG 160 Monotherapy 0.003 mg | Part 1A: AMG 160 Monotherapy 0.01 mg | Part 1A: AMG 160 Monotherapy 0.03 mg | Part 1A: AMG 160 Monotherapy 0.03 mg SD1 | Part 1A: AMG 160 Monotherapy 0.09 mg SD2 | Part 1A: AMG 160 Monotherapy 0.3 mg SD3 | Part 1A: AMG 160 Monotherapy 0.9 mg SD4 | Part 1A: AMG 160 Monotherapy 0.9 mg SD5 | Part 1A: AMG 160 0.9 mg + Tocilizumab SD6 | Part 1A: AMG 160 Monotherapy 0.9 mg SD7 | Part 1B1: AMG 160 Monotherapy 0.09 mg eIV1-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.3 mg eIV2-2d-Inf | Part 1B1: AMG 160 Monotherapy 0.3 mg eIV2-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.9 mg eIV3-2d-Inf | Part 1B1: AMG 160 Monotherapy 0.9 mg eIV3-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.6 mg eIV4-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.3 mg eIV5-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.3 mg eIV5-5d-Inf | Part 1B2: AMG 160 Monotherapy 0.09 mg eIVJC1-3d-Inf | Part 1B2: AMG 160 Monotherapy 0.3 mg eIVJC2-3d-Inf | Part 1: AMG Monotherapy Dose Expansion (DE) (0.3 mg) | Part 2: AMG 160 + Pembrolizumab 0.03 mg SDPC1 | Part 2: AMG 160 + Pembrolizumab 0.3 mg SDPC2 | Part 2: AMG 160 + Pembrolizumab 0.15 mg eIVPC3-3d-Inf | Part 2: AMG 160 + Pembrolizumab 0.3 mg eIVPC4-3d-Inf | Part 2: AMG 160 + Pembrolizumab 0.15 mg eIVPC3-3d-Inf D-RP2D | Part 3: AMG 160 With CRS Prophylaxis 0.9 mg SDEC1 | Part 3: AMG 160 With CRS Prophylaxis 0.3 mg eIVEC1-3d-Inf | Part 4: AMG 160 Monotherapy 0.3 mg 24HR | Part 5: AMG 160 Monotherapy 0.3 mg 8HR | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 18 - 64 years | 1 | 0 | 1 | 3 | 2 | 2 | 1 | 3 | 2 | 2 | 3 | 2 | 0 | 1 | 1 | 3 | 1 | 2 | 3 | 3 | 21 | 4 | 1 | 1 | 2 | 1 | 1 | 0 | 9 | 14 | 90 |
| 65 - 74 years | 2 | 4 | 0 | 0 | 3 | 2 | 3 | 0 | 1 | 2 | 2 | 1 | 2 | 1 | 0 | 0 | 1 | 4 | 0 | 2 | 27 | 0 | 2 | 4 | 5 | 2 | 2 | 2 | 12 | 8 | 94 |
| 75 - 84 years | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 2 | 0 | 1 | 2 | 7 | 2 | 0 | 0 | 0 | 0 | 0 | 1 | 4 | 1 | 26 |
| ≥ 85 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 2 |
| Sex: Female, Male(Participants) | Part 1A: AMG 160 Monotherapy 0.003 mg | Part 1A: AMG 160 Monotherapy 0.01 mg | Part 1A: AMG 160 Monotherapy 0.03 mg | Part 1A: AMG 160 Monotherapy 0.03 mg SD1 | Part 1A: AMG 160 Monotherapy 0.09 mg SD2 | Part 1A: AMG 160 Monotherapy 0.3 mg SD3 | Part 1A: AMG 160 Monotherapy 0.9 mg SD4 | Part 1A: AMG 160 Monotherapy 0.9 mg SD5 | Part 1A: AMG 160 0.9 mg + Tocilizumab SD6 | Part 1A: AMG 160 Monotherapy 0.9 mg SD7 | Part 1B1: AMG 160 Monotherapy 0.09 mg eIV1-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.3 mg eIV2-2d-Inf | Part 1B1: AMG 160 Monotherapy 0.3 mg eIV2-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.9 mg eIV3-2d-Inf | Part 1B1: AMG 160 Monotherapy 0.9 mg eIV3-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.6 mg eIV4-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.3 mg eIV5-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.3 mg eIV5-5d-Inf | Part 1B2: AMG 160 Monotherapy 0.09 mg eIVJC1-3d-Inf | Part 1B2: AMG 160 Monotherapy 0.3 mg eIVJC2-3d-Inf | Part 1: AMG Monotherapy Dose Expansion (DE) (0.3 mg) | Part 2: AMG 160 + Pembrolizumab 0.03 mg SDPC1 | Part 2: AMG 160 + Pembrolizumab 0.3 mg SDPC2 | Part 2: AMG 160 + Pembrolizumab 0.15 mg eIVPC3-3d-Inf | Part 2: AMG 160 + Pembrolizumab 0.3 mg eIVPC4-3d-Inf | Part 2: AMG 160 + Pembrolizumab 0.15 mg eIVPC3-3d-Inf D-RP2D | Part 3: AMG 160 With CRS Prophylaxis 0.9 mg SDEC1 | Part 3: AMG 160 With CRS Prophylaxis 0.3 mg eIVEC1-3d-Inf | Part 4: AMG 160 Monotherapy 0.3 mg 24HR | Part 5: AMG 160 Monotherapy 0.3 mg 8HR | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Male | 3 | 4 | 1 | 3 | 6 | 4 | 4 | 4 | 3 | 4 | 6 | 4 | 3 | 2 | 1 | 4 | 4 | 6 | 4 | 7 | 56 | 6 | 3 | 5 | 7 | 3 | 3 | 3 | 26 | 23 | 212 |
| Ethnicity (NIH/OMB)(Participants) | Part 1A: AMG 160 Monotherapy 0.003 mg | Part 1A: AMG 160 Monotherapy 0.01 mg | Part 1A: AMG 160 Monotherapy 0.03 mg | Part 1A: AMG 160 Monotherapy 0.03 mg SD1 | Part 1A: AMG 160 Monotherapy 0.09 mg SD2 | Part 1A: AMG 160 Monotherapy 0.3 mg SD3 | Part 1A: AMG 160 Monotherapy 0.9 mg SD4 | Part 1A: AMG 160 Monotherapy 0.9 mg SD5 | Part 1A: AMG 160 0.9 mg + Tocilizumab SD6 | Part 1A: AMG 160 Monotherapy 0.9 mg SD7 | Part 1B1: AMG 160 Monotherapy 0.09 mg eIV1-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.3 mg eIV2-2d-Inf | Part 1B1: AMG 160 Monotherapy 0.3 mg eIV2-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.9 mg eIV3-2d-Inf | Part 1B1: AMG 160 Monotherapy 0.9 mg eIV3-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.6 mg eIV4-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.3 mg eIV5-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.3 mg eIV5-5d-Inf | Part 1B2: AMG 160 Monotherapy 0.09 mg eIVJC1-3d-Inf | Part 1B2: AMG 160 Monotherapy 0.3 mg eIVJC2-3d-Inf | Part 1: AMG Monotherapy Dose Expansion (DE) (0.3 mg) | Part 2: AMG 160 + Pembrolizumab 0.03 mg SDPC1 | Part 2: AMG 160 + Pembrolizumab 0.3 mg SDPC2 | Part 2: AMG 160 + Pembrolizumab 0.15 mg eIVPC3-3d-Inf | Part 2: AMG 160 + Pembrolizumab 0.3 mg eIVPC4-3d-Inf | Part 2: AMG 160 + Pembrolizumab 0.15 mg eIVPC3-3d-Inf D-RP2D | Part 3: AMG 160 With CRS Prophylaxis 0.9 mg SDEC1 | Part 3: AMG 160 With CRS Prophylaxis 0.3 mg eIVEC1-3d-Inf | Part 4: AMG 160 Monotherapy 0.3 mg 24HR | Part 5: AMG 160 Monotherapy 0.3 mg 8HR | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 2 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 7 |
| Not Hispanic or Latino | 3 | 4 | 1 | 2 | 6 | 3 | 4 | 4 | 3 | 4 | 6 | 4 | 3 | 2 | 1 | 4 | 3 | 5 | 4 | 7 | 53 | 6 | 3 | 4 | 7 | 3 | 3 | 3 | 25 | 22 | 202 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 |
| Race (NIH/OMB)(Participants) | Part 1A: AMG 160 Monotherapy 0.003 mg | Part 1A: AMG 160 Monotherapy 0.01 mg | Part 1A: AMG 160 Monotherapy 0.03 mg | Part 1A: AMG 160 Monotherapy 0.03 mg SD1 | Part 1A: AMG 160 Monotherapy 0.09 mg SD2 | Part 1A: AMG 160 Monotherapy 0.3 mg SD3 | Part 1A: AMG 160 Monotherapy 0.9 mg SD4 | Part 1A: AMG 160 Monotherapy 0.9 mg SD5 | Part 1A: AMG 160 0.9 mg + Tocilizumab SD6 | Part 1A: AMG 160 Monotherapy 0.9 mg SD7 | Part 1B1: AMG 160 Monotherapy 0.09 mg eIV1-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.3 mg eIV2-2d-Inf | Part 1B1: AMG 160 Monotherapy 0.3 mg eIV2-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.9 mg eIV3-2d-Inf | Part 1B1: AMG 160 Monotherapy 0.9 mg eIV3-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.6 mg eIV4-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.3 mg eIV5-3d-Inf | Part 1B1: AMG 160 Monotherapy 0.3 mg eIV5-5d-Inf | Part 1B2: AMG 160 Monotherapy 0.09 mg eIVJC1-3d-Inf | Part 1B2: AMG 160 Monotherapy 0.3 mg eIVJC2-3d-Inf | Part 1: AMG Monotherapy Dose Expansion (DE) (0.3 mg) | Part 2: AMG 160 + Pembrolizumab 0.03 mg SDPC1 | Part 2: AMG 160 + Pembrolizumab 0.3 mg SDPC2 | Part 2: AMG 160 + Pembrolizumab 0.15 mg eIVPC3-3d-Inf | Part 2: AMG 160 + Pembrolizumab 0.3 mg eIVPC4-3d-Inf | Part 2: AMG 160 + Pembrolizumab 0.15 mg eIVPC3-3d-Inf D-RP2D | Part 3: AMG 160 With CRS Prophylaxis 0.9 mg SDEC1 | Part 3: AMG 160 With CRS Prophylaxis 0.3 mg eIVEC1-3d-Inf | Part 4: AMG 160 Monotherapy 0.3 mg 24HR | Part 5: AMG 160 Monotherapy 0.3 mg 8HR | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 4 | 7 | 10 | 0 | 0 | 0 | 2 | 1 | 0 | 0 | 0 | 1 | 29 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 5 | 15 |
| White | 2 | 4 | 1 | 3 | 6 | 1 | 3 | 2 | 2 | 3 | 5 | 4 | 2 | 2 | 1 | 4 | 4 | 2 | 0 | 0 | 33 | 6 | 3 | 4 | 4 | 2 | 3 | 3 | 20 | 17 | 146 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 2 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 12 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 22 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe, or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.
Data sharing details ↗ · www.amgen.com
Ran from Feb 2019 to primary completion in Jun 2023, 52 months.
Results were first posted in Nov 2026, 3 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is terminated, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Acapatamab